Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?

Abstract

Parkinson’s disease (PD) is the most common neurodegenerative disorder with motor symptoms. The neuropathological alterations characterizing the brain of patients with PD include the loss of dopaminergic neurons of the nigrostriatal system and the presence of Lewy bodies (LB), intraneuronal inclusions that are mainly composed of alpha-synuclein (α-Syn) fibrils. The accumulation of α-Syn in insoluble aggregates is a main neuropathological feature in PD and in other neurodegenerative diseases, including LB dementia (LBD) and multiple system atrophy (MSA), which are therefore defined as synucleinopathies. Compelling evidence supports that α-Syn post translational modifications (PTMs) such as phosphorylation, nitration, acetylation, O-GlcNAcylation, glycation, SUMOylation, ubiquitination and C-terminal cleavage, play important roles in the modulation α-Syn aggregation, solubility, turnover and membrane binding. In particular, PTMs can impact on α-Syn conformational state, thus supporting that their modulation can in turn affect α-Syn aggregation and its ability to seed further soluble α-Syn fibrillation. This review focuses on the importance of α-Syn PTMs in PD pathophysiology but also aims at highlighting their general relevance as possible biomarkers and, more importantly, as innovative therapeutic targets for synucleinopathies. In addition, we call attention to the multiple challenges that we still need to face to enable the development of novel therapeutic approaches modulating α-Syn PTMs.

1. Introduction

Parkinson’s disease (PD) is the second most common movement disorder, affecting 2% of the world population over 65 years of age (Baker and Graham, 2004).

Motor symptoms mainly arise from the loss of dopaminergic nigrostriatal neurons, that alters the homeostasis of basal ganglia networks (Hornykiewicz, 2001). Beyond motor manifestations, PD patients may also exhibit a wide range of non-motor and psychiatric symptoms, which are caused by functional changes in central nervous system (CNS) and peripheral network system (PNS) circuits (Pfeiffer, 2016; Engelender and Isacson, 2017; Takamatsu et al., 2018; Kulkarni et al., 2022).

Key neuropathological hallmark of PD is the deposition of insoluble proteinaceous inclusions in cell bodies and neurites (Gibb, 1986), which are called Lewy bodies (LB) and Lewy neurites (LN), respectively. In 1997, these were found to be mainly composed of alpha synuclein (α-Syn) insoluble fibrils (Spillantini et al., 1997). In the last decades, it has been shown that α-Syn is particularly enriched at synaptic terminals, where it regulates synaptic function (Spillantini et al., 1997; Burre et al., 2010; Longhena et al., 2019). Since then, other disorders such as LB dementia (LBD), multiple system atrophy (MSA), Alzheimer’s disease (AD) LB variant or neurodegeneration with brain iron accumulation (NBIA), have been found to be characterized by brain accumulation of insoluble α-Syn deposits, and have been defined as synucleinopathies (Spillantini et al., 1998; Spillantini, 1999; Spillantini and Goedert, 2016; Goedert et al., 2017).

Interestingly, α-Syn deposits have been observed also in the PNS innervating the gastrointestinal tract, blood, salivary glands, olfactory mucosa, skin, retina, adrenal gland, heart and muscles (Qualman et al., 1984; Fumimura et al., 2007; Beach et al., 2010; Gelpi et al., 2014; Zange et al., 2015; Stoessl, 2016; Rey et al., 2016a,b, 2018; Wakabayashi, 2020). This peripheral α-Syn pathology is thought to contribute to the onset of PD non-motor manifestations in the prodromal and symptomatic phase (Abbott et al., 2007).

Remarkably, numerous studies in experimental models of synucleinopathy, post-mortem PD brains and neuroimaging evidences support that α-Syn pathological aggregation can severely impair synaptic function, thus consequently perturbing neuronal network dynamics and inducing neurodegeneration (Bellucci et al., 2016, 2017; Longhena et al., 2017, 2019; Kulkarni et al., 2022). This notwithstanding, we still ignore the mechanisms that drive pathological α-Syn aggregation in neuronal cells, and this has hampered the development of innovative effective therapies that block α-Syn pathological deposition as disease modifying approaches for PD and other synucleinopathies (Fields et al., 2019; Lashuel, 2021; Oliveira et al., 2021; Engelender et al., 2022). Indeed, current α-Syn-targeting strategies mainly include immunotherapy-based removal of extracellular α-Syn fibrils, gene therapy-based reduction of α-Syn, general and non-selective small molecule inhibitors of protein aggregation and protein degradation enhancers, but we still miss a cutting edge approach interfering with the culprit of α-Syn aggregate formation.

Interestingly, several post translational modifications (PTMs) of α-Syn have been found to differently modulate α-Syn aggregation either by predisposing or interfering with it (Zhang et al., 2019; Table 1). Indeed, they can affect α-Syn aggregation propensity, solubility and turnover, membrane binding and interaction with other proteins and metals (Oueslati et al., 2010; Zhang et al., 2017, 2019; Bell and Vendruscolo, 2021; Bell et al., 2022a,b). Moreover, α-Syn PTMs can serve as markers for environmental changes, may play a role in gene expression by impinging on cellular responses to stimuli and are also under study as possible disease biomarkers for synucleinopathies (Vicente Miranda et al., 2017a; Fayyad et al., 2019; Vivacqua et al., 2019; Petricca et al., 2022; Sonustun et al., 2022).

In this review, we summarize and discuss the main findings on α-Syn PTMs, in order to define a route to decipher whether these modifications can be rationally considered as achievable druggable targets for synucleinopathies or effective biomarkers monitoring the progression or enabling patient stratification in these neurodegenerative disorders.

2. α-Syn and its post-translational modifications

α-Syn is a member of synuclein family, which also includes β-and γ-synuclein (Clayton and George, 1998). In humans, α-Syn is encoded by the SNCA gene located on chromosome 4q21 (Shibasaki et al., 1995; Lavedan, 1998).

Although the physiological role of α-Syn has not been fully elucidated yet, numerous studies demonstrated its involvement in the control of synaptic release. Indeed, it regulates synaptic vesicle clustering, the coupling and fusion of vesicles participating in SNARE complex assembly, the extent of phasic and tonic neurotransmitter release as well as neurotransmitter reuptake (Choi et al., 2013; Ghiglieri et al., 2018; Longhena et al., 2019). Moreover, α-Syn regulates mitochondrial function, fusion as well as mitochondria and endoplasmic reticulum interaction at mitochondria-associated membranes (MAM; Dauer et al., 2002; Ellis et al., 2005; Di Maio et al., 2016; Ludtmann et al., 2016; Menges et al., 2017; Faustini et al., 2019; Risiglione et al., 2021; Thorne and Tumbarello, 2022) and is involved in neuronal plasticity (Liu et al., 2004b, 2007; Watson et al., 2009; Ullman et al., 2011; Leite et al., 2022; Calabresi et al., 2023).

α-Syn is composed of 140 amino acids and its molecular weight is 14 kDa. α-Syn structure encompasses 3 domains: (1) the N-terminal region (residues 1–60), is positively charged and contains imperfect repeats with a highly conserved hexameric motif (KTKEGV), typically involved in the formation of amphipathic α-helices which mediate membrane binding (Clayton and George, 1998; George, 2002; Vamvaca et al., 2009); (2) the central hydrophobic region (residues 61–95), also known as non-amyloid component (NAC) portion, is prone to intermolecular interactions and is crucial for aggregation and fibril formation (Giasson et al., 2001; Ma et al., 2003); (3) the C-terminal region (residues 96–140) is highly enriched in acidic proline residues (Bellucci et al., 2012). This part of the protein reduces the NAC propensity for aggregation, mediates the majority of α-Syn interactions with proteins, metal ions and other ligands, including dopamine and polyamines, and harbors the majority of PTMs sites (Jensen et al., 1999; Paik et al., 1999; Giasson et al., 2003; Fernandez et al., 2004; Hoyer et al., 2004; Brown, 2007).

α-Syn does not present a defined structure in aqueous solutions and for this reason is defined “natively unfolded” (Stefanis, 2012), but it can shift to α-helix structure in association with membrane phospholipids, suggesting that it acquires different roles in different subcellular compartments based on its dynamic structure (Ahn et al., 2002). Indeed, in function of its capacity to acquire different conformations, α-Syn can interact with lipid membranes, enzymes, chaperones, synaptic and cytoskeletal proteins. Some studies also suggested a physiological α-helical structure forming dimers that counteract synaptic vesicle fission or tetramers that resist aggregation (Bartels et al., 2011; Wang et al., 2011; Medeiros et al., 2017).

Compelling evidence supports that PTMs play an important role in promoting conformational changes that make α-Syn more or less prone to aggregation (Table 1). Indeed, several PTMs such as phosphorylation, nitration, acetylation, glycation, truncation, ubiquitination, SUMOylation and O-GlcNAcylation can affect α-Syn structure. In particular, PTMs can either promote or inhibit α-Syn oligomerization, fibrillization and degradation (Feany and Bender, 2000; Fujiwara et al., 2002; Hodara et al., 2004; Smith et al., 2005a; Kasai et al., 2008; Lee et al., 2008; Rott et al., 2008, 2017; Tetzlaff et al., 2008; Danielson et al., 2009; Oueslati et al., 2010, 2013; Levine et al., 2017; Lewis et al., 2017; Zhang et al., 2019). Moreover, it has been described that LB contain phosphorylated, nitrated, ubiquitinated, SUMOylated and C-terminally truncated α-Syn, further supporting the role of PTMs in the modulation of α-Syn aggregation (Baba et al., 1998; Crowther et al., 1998; Giasson et al., 2000; Gomez-Tortosa et al., 2000; Campbell et al., 2001; Hasegawa et al., 2002; Anderson et al., 2006; Paleologou et al., 2010; Rott et al., 2017).

3. α-Syn post-translational modifications as possible biomarkers for PD and other synucleinopathies

Of note, α-Syn and post translational modified α-Syn in peripheral and accessible tissues have been investigated as possible biomarkers for the diagnosis of PD and other synucleinopathies. Nevertheless, since none of them has been validated across different cohorts so far, we still miss a clear cut evidence supporting their factual clinical significance (Witt et al., 2009; Pouclet et al., 2012; Shannon et al., 2012; Donadio et al., 2014, 2018; Sprenger et al., 2015; Zange et al., 2015; Stokholm et al., 2016; Vilas et al., 2016; Fereshtehnejad et al., 2017).

Biomarkers are defined as cellular, biochemical or molecular alterations that are measurable in biological samples such as human tissues, cells, or fluids (Hulka, 1990). The definition has been extended in order to define biomarkers as biological characteristics that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention (Naylor, 2003). In particular, biomarkers include tools and technologies that can help disease prediction, cause, diagnosis, progression, regression, or the outcome of treatments (Mayeux, 2004). The importance of biomarkers is particularly relevant in the context of diseases affecting CNS, where it is impossible to have the direct access to the unhealthy tissue. CNS biomarkers detection can be pursued by positron emission tomography (PET) or magnetic resonance imaging (MRI) as well as by biological fluids [blood, cerebrospinal fluid (CSF), saliva], skin and gastrointestinal system biopsies or nasal mucosa analysis.

The fact that α-Syn can be found in different forms (monomeric, oligomeric, aggregated or post translational modified) in accessible and peripheral tissues such as CSF, blood, saliva, tears, colon, esophagus and skin (Tokuda et al., 2010; Devic et al., 2011; Foulds et al., 2011, 2012; Mollenhauer et al., 2013; Abd-Elhadi et al., 2015; Koehler et al., 2015; Chung et al., 2016; Cariulo et al., 2019; Fenyi et al., 2019; Hamm-Alvarez et al., 2019; Vivacqua et al., 2019; Maass et al., 2020; Wang et al., 2020b; Tanei et al., 2021; Bakhit et al., 2022), opened up the possibility to evaluate whether these different proteoforms may be useful for the diagnosis of PD and or other synucleinopathies (Witt et al., 2009; Pouclet et al., 2012; Shannon et al., 2012; Donadio et al., 2014, 2018; Sprenger et al., 2015; Zange et al., 2015; Stokholm et al., 2016; Vilas et al., 2016; Fereshtehnejad et al., 2017; Fayyad et al., 2019; Parnetti et al., 2019; Vivacqua et al., 2019, 2023; Wang et al., 2020b; Ganguly et al., 2021).

Several studies demonstrated that the levels of α-Syn phosphorylated at serine 129 (p-ser129), a PTM that is considered a marker of mature α-Syn aggregates (Ghanem et al., 2022), are elevated in the CSF and plasma of PD patients (Foulds et al., 2011, 2012; Wang et al., 2014; Landeck et al., 2016; Majbour et al., 2016a,b), while total α-Syn levels are decreased (Vivacqua et al., 2019, 2023). Remarkably, the levels of p-ser129 α-Syn were also found to significantly correlate with symptom severity in PD patients, suggesting that p-ser129 may serve as a biomarker for disease progression (Wang et al., 2014; Stewart et al., 2015).

In a recent study, increased levels of total and aggregated α-Syn in the membrane fraction of erythrocytes and high levels of p-ser129 α-Syn in cytosolic fractions were detected in PD cases versus healthy controls (Tian et al., 2019). Another report that analyzed oxidized and p-ser129 α-Syn demonstrated that higher levels of total and proteinase K resistant α-Syn and p-ser129 α-Syn can be detected in PD patients with motor symptoms (without dementia) with a high degree of accuracy (Abd Elhadi et al., 2019). Interestingly, p-ser129 α-Syn can be detected in skin nerve fibers biopsies and saliva (Vivacqua et al., 2019, 2023; Bougea et al., 2019a; Infante et al., 2020; Wang et al., 2020a; De Bartolo et al., 2023). Interestingly, α-Syn isolated from the skin and saliva has aggregation seeding activity and could serve as a biomarker for PD and as a differential biomarker to distinguish synucleoinopathies from tauopathies (Wang et al., 2020b).

p-ser129 α-Syn has also been detected in the lysate of red blood cells in synucleinopathies (Tian et al., 2019; Li et al., 2020, 2021). Higher levels of both Tyrosine (tyr) 125-phosphorylated α-Syn (p-tyr125) and p-ser129 α-Syn can be also detected in the blood of PD patients (Foulds et al., 2011, 2013; Vicente Miranda et al., 2017a).

Two recent meta-analysis showed that patients with PD have higher blood oxidative stress (OS) markers such as malondialdehyde (MDA), 8-Oxo-2′-deoxyguanosine lipid hydro-peroxide, nitrate and ferritine and lower antioxidant activity of superoxide dismutase (SOD), glucose 6 phosphate dehydrogenase, catalase, and glutathione peroxidase (GPx) compared with healthy control (Khan and Ali, 2018). Nitration of tyr and tryptophan residues as a consequence of the formation of peroxynitrite byproducts easily occurs at OS sites, i.e., in inflamed tissue, and can alter the structure and function of proteins. Nitric oxide (NO) and superoxide react to form peroxynitrite which promotes the nitrification of tyr residues in proteins. Specifically, the nitro group (−NO₂) is added to replace a hydrogen atom in the 3′ position of the tyr phenolic ring to form 3-nitrotyrosine (Chavarria and Souza, 2013). Several studies reported the presence of nitrated α-Syn in in vivo and in vitro experimental models of PD and also in LB (Giasson et al., 2000; Yu et al., 2010; He et al., 2019; Manzanza et al., 2021; Simon et al., 2021; Magalhaes and Lashuel, 2022). Of note, Fernandez et al. (2013) reported the presence of tyr125/136 nitrated α-Syn in the CSF and serum of early PD patients, while a more recent study showed increased levels of nitrated α-Syn at tyr39 (n-tyr39) in the red blood cells of PD patients (Vicente Miranda et al., 2017a). In the same study, Vicente Miranda et al. (2017a) showed also reduced levels of SUMOylated α-Syn and increased levels of glycated α-Syn in PD patients erythrocytes with respect to controls. Since SUMOylation can increase α-Syn solubility and reduce aggregation (Krumova et al., 2011) and glycation can potentiate neuronal loss and motor impairment (Vicente Miranda et al., 2017b), the observed results may reflect brain α-Syn pathological alterations and toxicity (Vicente Miranda et al., 2017a,b).

These findings suggest that α-Syn PTMs, and in particular α-Syn nitration or phosphorylation, can be valuable biomarkers for synucleinopathies. This notwithstanding, we miss large cross-sectional and follow-up studies that will be pivotal for the implementation of post-translationally-modified α-Syn as a biomarker and we need to standardize the most reliable detection methods and several technical issues dealing with the detection or quantification of α-Syn have to be solved (Schmid et al., 2013; Mollenhauer et al., 2017; Magalhaes and Lashuel, 2022; Petricca et al., 2022). Indeed, the assay developed in the different studies exhibited different sensitivity and specificity and also led to conflicting results (Malek et al., 2014; Vivacqua et al., 2019, 2023; Bougea et al., 2019a,b; De Bartolo et al., 2023). For instance, Lin et al. (2019) recently reported a marked increase in total and phosphorylated α-Syn levels as well as in their ratio in the plasma of PD patients vs. healthy controls with assays exhibiting elevated specificity (AUC of ROC curves: 0.94, 0.91 and 0.74, respectively). This is in contrast to the findings of a previous study (Foulds et al., 2012) describing a reduction of total α-Syn and a parallel increase in phosphorylated α-Syn levels detected in the plasma of PD patients with a phosphorylated α-Syn assay exhibiting a ROC AUC = 0.68. Consistently, other reports showed that levels of phosphorylated α-Syn are increased in spite of the decrease of total α-Syn levels in plasma of PD patients (Hong et al., 2010; Gorostidi et al., 2012; Cariulo et al., 2019). When considering that because of sensitivity and specificity issues even CSF or plasma α-Syn cannot be considered as valuable markers of PD yet, it is clear that, as the reliable detection of post-translationally modified α-Syn is even more problematic, much work is warranted for achieving the exhaustive clinical translation of these kind of assay. This notwithstanding, the integrated measurement of α-Syn PTM may offer the possibility to single out patient-specific signatures that in the future could be of great help to settle precision-medicine-based approaches if disease-modifying therapies targeting α-Syn pathology will be developed.

4. Phosphorylation

Among α-Syn PTMs, phosphorylation is the most studied. The primary cause of this interest is mainly due to the fact that in normal brains only 4% of α-Syn is phosphorylated, whereas in LB extracted from PD brains 90% of α-Syn is phosphorylated at ser87 (p-ser87) and at ser129 (Anderson et al., 2006; Paleologou et al., 2010). Other sites of phosphorylation have been found on tyr residues at position 39, 125, 133, and 136.

Phosphorylation is the chemical addition of a phosphoryl group (PO³⁻) to an organic molecule. Phosphorylation and dephosphorylation (the removal of a phosphoryl group) are carried out by enzymes (e.g., kinases, phosphatases) and the processes orchestrate a plethora of cellular functions in response to external stimuli. In vitro and cell culture-based studies have identified a number of kinases, which phosphorylate α-Syn at ser129 and/or ser87, including casein kinase I (CKI; ser87 and ser129), casein kinase II (CKII; ser129; Okochi et al., 2000), G protein-coupled receptor kinases (GRKs 1, 2, 5 and 6; ser129; Pronin et al., 2000), leucine-rich repeat kinase 2 (LRRK2; ser129; Qing et al., 2009b), polo-like kinase (PLK; ser129; Inglis et al., 2009, Mbefo et al., 2010) protein kinase C-related kinase (PKR; ser129; Reimer et al., 2018) and LK6/Mnk2a (ser129; Zhang et al., 2015).

α-Syn phosphorylation at tyr125 can be mediated by the proto-oncogene tyrosine-protein kinase Fyn (Nakamura et al., 2001) and SRC proto-oncogene non-receptor (Src) tyr kinases such as spleen associated tyrosine kinase (Syk), the non-receptor tyrosine-protein kinase Lyn, the protein tyrosine kinase expressed by the protooncogene c-fgr (Ellis et al., 2001; Negro et al., 2002). Syk also phosphorylates α-Syn at try133 and tyr136.

Although the contribution of α-Syn pathology to LRRK2-associated PD is debated (Schneider and Alcalay, 2017) and the relevance of LRRK2-mediated α-Syn phosphorylation in PD is still to be determined, several studies reported that LRRK2 co-localizes with α-Syn in the lower brainstem of PD and LBD patients at early stages (Alegre-Abarrategui et al., 2008; Qing et al., 2009b; Zimprich et al., 2011). Still, in vitro studies hint that G2019S-mutant LRRK2 exhibit an improved ability to phosphorylate α-Syn on ser129 when compared to wt LRRK2 (Qing et al., 2009a).

On the other hand, the phosphatases involved in the dephosphorylation are phosphoprotein phosphatase 2A and 2C (PP2A and PP2C).

Increased ser129 α-Syn phosphorylation has been detected in PD, LBD and MSA (Kahle et al., 2000; Okochi et al., 2000; Fujiwara et al., 2002; Takahashi et al., 2003; Anderson et al., 2006). A recent study analyzing post-mortem tissue from PD and MSA patients at different disease stages reported that ser129 α-Syn phosphorylation is the dominant and earliest PTMs, while lower amounts of p-ser87 α-Syn appeared later along PD progression (Sonustun et al., 2022).

Almost all phosphorylation sites cluster at the C-terminal region of α-Syn (residues 120–140), which is involved in protein–protein, protein-ligand and protein-metal interactions, suggesting a possible role of the modification in the regulation of these functions. Only ser87 lies in the hydrophobic NAC region of α-Syn, which is essential for α-Syn aggregation and fibrillogenesis (El-Agnaf et al., 1998b).

Ser129 is the most studied phosphorylation site because it was linked with increased cytotoxicity and neuronal death (Zhang et al., 2015; Karampetsou et al., 2017; Zhong et al., 2017; Reimer et al., 2018). Furthermore, it has been described that p-ser129 enhances intracellular aggregate formation in SH-SY5Y cells (Smith et al., 2005b) and mediates cell death through activation of the unfolded protein response (UPR) pathway (Sugeno et al., 2008). Still, Karampetsou et al. (2017) observed that mice who received intrastriatal injection of p-ser129 α-Syn exhibited enhanced α-Syn pathology deposition and neurodegeneration in the substantia nigra (SN) compared to the mice injected with wild type (wt) α-Syn.

However, other studies in cellular and animal models claimed that phosphorylated α-Syn exherts a neuroprotective role (Gorbatyuk et al., 2008; Oueslati et al., 2012; Tenreiro et al., 2014; Ghanem et al., 2022). In particular, it has been demonstrated that p-ser129 phosphorylation occurs secondarily to α-Syn accumulation, reducing cytotoxicity and aggregation propensity of α-Syn (Ghanem et al., 2022). Interestingly, p-tyr125 α-Syn can also prevent α-Syn neurotoxicity and aggregation and is pivotal for ser129 phosphorylation (Kosten et al., 2014).

The role of p-ser87 is also controversial as this PTM falls in the NAC region of α-Syn, which is crucial for α-Syn aggregation and fibrillogenesis in vitro (Ueda et al., 1993; El-Agnaf et al., 1998a,b; Giasson et al., 2001). In addition, though p-ser87 phosphorylation is increased in the membrane fractions of post mortem brains of patients affected by LBD, MSA and AD and healthy controls and of rats overexpressing wt α-Syn, p-ser87 was found to reduce α-Syn membrane binding (Paleologou et al., 2010), supporting that this phosphorylation may be crucial for modulating the physiological effect of α-Syn on synaptic vesicle mobility. Moreover, the unilateral p-ser87 α-Syn overexpression in the nigrostriatal system of rats results in reduced formation of aggregates and does not exert toxicity for nigral dopaminergic neurons in contrast to what has been observed following wt α-Syn overexpression (Decressac et al., 2012; Lundblad et al., 2012; Oueslati et al., 2012; Faustini et al., 2018).

Differently, p-tyr125 was reported to decrease with aging and in PD brains, in Drosophila melanogaster and mice (Chen et al., 2009). As this phosphorylation has been found to reduce α-Syn oligomerization, it has been hypothesized that it may play a protective role against aggregate formation (Chen et al., 2009). On this line, Negro et al. (2002) showed that the kinase Syk phosphorylates the C-terminal tyr125 of α-Syn to block α-Syn fibrillation. Moreover, p-tyr125 facilitates the deposition of p-ser129 under physiological conditions (Kosten et al., 2014).

PLK2 has been found to phosphorylate α-Syn, but not β-or γ-syn, at ser129 in HEK293T cells and in primary neurons (Arawaka et al., 2006; Inglis et al., 2009; Mbefo et al., 2010). In particular, PLKs can phosphorylate both monomeric or fibrillary α-Syn (Waxman and Giasson, 2011) and overexpression of PLK2 enhances α-Syn turnover via the autophagic degradation pathway, thus suppressing its toxicity in vivo (Oueslati et al., 2013). Despite the role of PLK2 in centriole duplication and cell cycle regulation, PLK2 inhibitors do not appear to cause cytotoxicity nor genotoxicity in vitro or in vivo at doses and exposures that engage the target in rat (Fitzgerald et al., 2013), but clinical trials on PLK2 inhibitors have shown difficulties in targeting specifically PLK2 in order to avoid off-target-related side effects (Vancraenenbroeck et al., 2011).

c-Abelson tyrosine kinase (c-Abl) is a 120 kDa protein majorly known in relation to human leukemias. c-Abl is distributed in the nucleus and cytosol and is involved in a wide range of functions, including apoptosis and development of the CNS in which it affects neurogenesis, neurite outgrowth, and neuronal plasticity. Moreover, it is involved in several neurodegenerative diseases including PD (Tremblay et al., 2010; Imam et al., 2011). For instance, c-Abl is elevated in postmortem nigrostriatal region of PD patients (Ko et al., 2010; Imam et al., 2011) where it is majorly phosphorylated at tyr412 (Mehdi et al., 2016). c-Abl was found to phosphorylate parkin thus impairing its E3 ligase activity and leading to the loss of dopaminergic neurons in the SN (Ko et al., 2010). It has been described that c-Abl aberrant activation induced a progressive accumulation of α-Syn in the human A53T mutant α-Syn tg mouse model of genetic PD (Brahmachari et al., 2016) through the phosphorylation at tyr39 (Mahul-Mellier et al., 2014; Brahmachari et al., 2016; Dikiy et al., 2016), thus contributing to neurodegeneration. Furthermore, c-Abl is activated by OS (Brasher and Van Etten, 2000; Sun et al., 2000; Gonfloni et al., 2012), and in turn it disrupts antioxidant defense mechanisms driving oxidative injury (Li et al., 2004). It may thus be inferred that c-Abl inhibitors may impact on α-Syn pathology by affecting the phosphorylation and nitration state of the protein.

Consistently, Hebron et al. (2013) showed that c-Abl activation promotes α-Syn accumulation and that the treatment with nilotinib, a brain-permeable second-generation c-Abl inhibitor, developed from the first generation anticancer agent, named imatinib, favored the clearance of α-Syn, improved motor performances (Hebron et al., 2013), restored the levels of dopamine transporter (DAT) and dopamine production in the striatum as well as the expression of tyrosine hydroxylase (TH) in the SN (Hebron et al., 2013, Karuppagounder et al., 2014; Table 2).

Of note, results from nilotinib clinical trials showed that the drug could reduce oligomeric α-Syn (only at 150 mg dose) as well as phosphorylated tau. Nilotinib treatment also improved dopamine metabolism in patients with PD. In particular, it increased the levels of homovanillic acid (HVA) and 3,4-Dihydroxyphenylacetic acid (DOPAC) in the CSF (Pagan et al., 2016, 2020) but without improving motor and nonmotor outcomes.

Simuni et al. (2021) run a double-blind, placebo-controlled trial on 173 PD patients. The results about safety, tolerability, adverse effects and lack of the symptomatic effect of nilotinib were in line with the study by Pagan et al. (2020). However, they could not observe changes in biomarkers. Although these evidences support that nilotinib is not suitable for further testing the collected data did not exclude the importance of c-Abl modulation in PD therapeutic strategy (Simuni et al., 2021).

The fact that no clinically meaningful benefit in PD patients in two double-blind studies was reported, is discouraging, but this can find an explanation by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c-Abl. As a competitive inhibitor of c-Abl with an IC50 of ≈48 nM it would require a sustained concentration of 150 nM to exert the adequate functions (Pagan et al., 2019). Other c-Abl inhibitors such as IkT-148,009 and vodobatinib (Table 2), are currently under development. The chronic oral treatment with IkT-148,009 was found to significantly reduce p-tyr39 and p-ser129 α-Syn levels thus preventing neurodegeneration in the brain of human A53T mutated α-Syn transgenic (tg) mice and of mice who received striatal injections of mouse recombinant α-Syn pre-formed fibrils (PFF; Karuppagounder et al., 2023). IkT-148009 is a derivative of the commercial anticancer imatinib and it has an IC50 of 33 nM for c-Abl, an improvement in potency of more than 20-fold over imatinib (Werner and Olanow, 2022). The randomized phase I/Ib study in older adult or elderly healthy volunteer was then extended to PD patients to identify the safety, tolerability, maximum tolerated dose and the pharmacokinetic profile of the molecule in single doses up to 325 mg and multiple doses up to 100 mg (Clinical trial identifier: NCT04350177). A randomized, double-blind study in non-treated PD patients is also ongoing (Clinical trial identifier: NCT05424276).

Vodobatinib, also known as K0706 or as SCC-138 is a chemical mixture of other two commercial anticancer agents (Dasatinib and Ponatinib) and it has a reported IC50 for wt c-Abl of 0.9 nM (Antelope et al., 2019). In preclinical models of PD it has been shown that it inhibited preferentially, with a sub-nanomolar potency, the protein kinase activity of c-Abl. Moreover, it increased autophagic flux, it had appreciable BBB penetration in vivo and protected both 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice and rats overexpressing α-Syn from nigrostriatal neuron loss (Mandhane et al., 2019).

A phase I clinical trial showed that vodobatinib was well-tolerated and allowed the selection of two doses that are likely to produce therapeutic effects (Clinical trial identifier: NCT03316820). A new double-blind, placebo-controlled phase II study is now recruiting for evaluating the safety and effectiveness of the two selected K0706 doses in people with early PD who are not receiving dopaminergic therapy (Clinical trial identifier: NCT03655236). The primary endpoints focus on changes from baseline in the sum of Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts 2 and 3, but among other outcome measures there will be the evaluation of CSF and blood K0706 levels and dopamine transporter single-photon emission computed tomography (DAT-SPECT).

Collectively, the above summarized studies on c-Abl inhibitors support that the use of protein kinase modulators in PD may be beneficial. Nevertheless, we need to achieve a deeper understanding of the role of the α-Syn phosphorylation and, more generally, on protein kinase and phosphatases activity in synucleinopathies, before to conclude that strategies modulating this PTM may constitute a possible therapeutic approach for this class of neurodegenerative disorders.

5. Nitration

Post-mortem PD brains are rich in lipid peroxidation products such as 4-hydroxyl-2-nonenal (HNE) as well as DNA and RNA oxidation products (Alam et al., 1997; Floor and Wetzel, 1998; Zhang et al., 1999). Moreover, several lines of evidence support that OS is involved in the degeneration of dopaminergic neurons in PD (Jenner and Olanow, 2006; Schapira and Tolosa, 2010).

OS is the result of a disequilibrium between the production of reactive oxygen species (ROS) or reactive nitrogen species (RNS) and the system for the detoxification leading to the production of free radicals byproducts that damage proteins, lipids, nucleic acids and organelles (Ryan et al., 2014). Although the brain represents only 2% of the body weight, it consumes 20% of the total body oxygen (Quastel and Wheatley, 1932; Magistretti and Pellerin, 1996), which is majorly converted in ROS. To defend against oxidative injuries, cells own a series of enzyme-based antioxidant mechanisms, such as glutathione (GSH), SOD and DJ-1. However, these systems are feeble in preventing the damage. In particular, nigral dopaminergic neurons are particularly sensitive to oxidative injuries as they own long, highly branched axons with a huge number of release sites that renders these cells bioenergentically demanding and at risk of developing mitochondrial OS (Pissadaki and Bolam, 2013). Nigral dopaminergic neurons also own a pacemaking activity characterized by broad and slow action potentials in the absence of synaptic input (Grace and Bunney, 1983). This activity engages continuously L-type Ca²⁺ channel, creating a basal mitochondrial OS in SN dopaminergic neurons (Guzman et al., 2010) and elevating intracellular Ca²⁺ levels (Wilson and Callaway, 2000; Chan et al., 2007). In light of the fact that cytoplasmic Ca²⁺ controls a huge number of pathways within a cell, its presence inside a neuron must be strictly controlled, and it is rapidly sequestered or pumped back in an ATP-dependent manner, thus resulting highly energy demanding (Wilson and Callaway, 2000). Still, dopamine turnover by monoamine oxidases (MAO) is involved in the production of cytotoxic free radicals, causing the death of dopaminergic neurons (Greenamyre and Hastings, 2004). Among them, the MAO-derived dopamine catabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) exhibits an enhanced reactivity towards proteins especially at synaptic terminals (Rees et al., 2009) and has been recently found to contribute to the initiation of α-Syn-dependent impaired proteostasis and degeneration of neuronal projections in different experimental models of PD (Masato et al., 2023).

Consistently, it is well established that mitochondria dysfunction is crucially involved in the pathogenesis of PD. This is also supported by the fact that several gene mutations implicated in familial and idiopathic forms of PD are located on loci encoding for mitochondria-linked proteins (Moore et al., 2005; Abou-Sleiman et al., 2006; Schapira, 2008). Moreover, postmortem studies on the SN of sporadic PD patients reported a decreased activity of mitochondrial complex I and higher levels of iron in the SN (Mann et al., 1994; Keeney et al., 2006). Free iron is toxic since it can donate or accept an electron from neighboring molecules and cause damage to cellular components and it can create ROS through the Fenton and Haber-Weiss reaction, in which ferric iron (Fe³⁺) and ferrous iron (Fe²⁺) react with superoxide and hydrogen peroxide to form hydroxyl radical (Beard and Connor, 2003; Jomova and Valko, 2011; Eid et al., 2017). Neuromelanin, the dark colored granular pigment present in the dopaminergic neurons of the SN, has the ability to chelate metals, in particular the ferric Fe³⁺ form (Gerlach et al., 2003), thus blocking the Fenton reaction and protecting the cells from hydroxyl radical production. The huge increase of iron found in SN of PD brains might saturate the iron-chelating site of neuromelanin, increasing the production of free radical species. Finally, neuroinflammation can also contribute to OS in the PD brain (Mosley et al., 2006; Picca et al., 2020; Teleanu et al., 2022).

The interplay between α-Syn and OS is still not fully elucidated. In vitro and in vivo studies support that increased OS in the brain may promote α-Syn aggregation (Paxinou et al., 2001), but α-Syn itself can increase ROS production (Junn and Mouradian, 2002; Winklhofer and Haass, 2010) or it can bind to mitochondrial complex I causing mitochondrial dysfunction in turn favoring OS (Chinta et al., 2010; Winklhofer and Haass, 2010; Wilkaniec et al., 2013).

Nitrated α-Syn can be easily formed under OS conditions. α-Syn has four tyr residues, placed in positions 39 (at the N-terminal region), 125, 133, and 136 (at the C-terminal region). The positions of the nitration sites suggest a possible modulation of membrane binding ability (Hodara et al., 2004) and protein–protein and protein-metal interactions. α-Syn is sensitive to the presence of nitrating agents and the presence of peroxynitrite not only induces the deposition of 3-nitrotyrosines but also the formation of 3,3-dityrosine via the oxidation of tyr residues, which results in α-Syn dimers and oligomer formation (Souza et al., 2000). Danielson et al. (2009) demonstrated a selective 9-fold increase in nitration on tyr39 of α-Syn in oxidative cellular model of PD. In addition, nitration of tyr39 induces high rate of oligomerization (Hodara et al., 2004) similarly to n-tyr125 that contributes to α-Syn dimer formation upon the exposure of recombinant α-Syn to nitrating agents (Takahashi et al., 2002).

Interestingly, a recent study analyzing post-mortem tissue from PD and MSA patients at different disease stages reported that ser129 α-Syn phosphorylation is the dominant and earliest PTMs, followed by tyr39 nitration, while lower amounts of p-ser87 α-Syn appeared later along PD progression (Sonustun et al., 2022). However, in the MSA brain glial cytoplasmatic inclusions, neuronal inclusions and small threads are mainly positive for tyr39 nitrated while ser129 α-Syn can be mainly detected in Schwan cell and neuronal inclusions (Sonustun et al., 2022; Wakabayashi et al., 2022).

Nitrated α-Syn monomers and dimers have been shown to accelerate fibril formation while nitrated α-Syn oligomers inhibit this process (Hodara et al., 2004). This supports that improving the amount of nitrated α-Syn oligomers may delay the formation of mature fibrils. This notwithstanding, as we still ignore whether fibrils or oligomers are the major neurotoxic species in PD, it is hard to predict whether this may be beneficial or detrimental.

Nevertheless, it may be feasible that antioxidant supplementation may be used to reduce α-Syn nitration. In this framework, some antioxidant schemes have been attempted, such as the supplementation of vitamin C, E and β-carotene as well as an adequate diet (Percario et al., 2020). Vitamin A and its precursor β-carotene, have been involved in the destabilization of fibrillary α-Syn in vitro (Ono et al., 2004; Ono and Yamada, 2007). Vitamin E (i.e., α-tocopherol) and Vitamin C (i.e., ascorbic acid) are antioxidants that are thought to have a protective effect by either reducing or preventing oxidative damage, preventing or interacting directly with free radicals, respectively. A lot of studies tried to investigate the relation between the intake of vitamins and the protection from PD, but they generated only conflicting results (Kieburtz et al., 1994; Hellenbrand et al., 1996; Morens et al., 1996; de Rijk et al., 1997; Scheider et al., 1997; Etminan et al., 2005; Miyake et al., 2011; Hughes et al., 2016; Schirinzi et al., 2019; Zhao et al., 2019). It has been demonstrated that NXP031, a new compound composed of aptamin C and vitamin C, blocks α-Syn aggregation in the hippocampus of AAV-human α-Syn-injected mice (Song et al., 2022). Similarly, also vitamin B12 was found to inhibit α-Syn fibrillogenesis in in vitro models (Jia et al., 2019).

Recent studies on MPTP in vivo and in vitro models support that γ-and δ-tocotrienol reduces dopaminergic neuron toxicity and improves motor performances through estrogen receptor/PI3K/Akt signaling pathway activation, hence in an antioxidant-independent way (Matsura, 2019). The supplementation of α-and δ-tocotrienol significantly ameliorates motor behavior and prevents the loss of nigra dopaminergic neurons and striatal fibers and neuroinflammation in 6-Hydroxydopamine (6-OHDA)-injected rats (Kumari et al., 2021). The vitamin E family compound tocotrienol is currently under study as a potential agent to delay motor symptoms in PD patients at Hoehn & Yahr stage 2 in a phase II clinical trial (Clinical trial identifier: NCT04491383; Table 3).

This notwithstanding, a multicenter, phase II, randomized, double-blind trial in early drug-naïve PD patients evaluating the efficacy of the iron chelator deferiprone (Table 3) on disease progression indicate that 36 weeks of therapy with deferiprone could remove specifically, safely and gradually the iron content in the nigrostriatal system of PD patients but it worsened the progression of symptoms (Devos et al., 2022). Studies on the efficacy of deferiprone in experimental in vivo models of synucleinopathies led to conflicting results. Indeed, human A57T α-Syn tg mice showed improvement in behavioral performances upon deferiprone treatment but without reduction of α-Syn aggregation (Carboni et al., 2017), while deferiprone treated mouse model of MSA exhibited rescued motor performance, higher neuronal survival and reduced density of α-Syn aggregates in SN (Shukla et al., 2021).

Another possible strategy to counteract OS is based on GSH rebalancing. In particular, since GSH is neither able to pass the blood brain barrier (BBB) nor the cellular membrane of neurons, the dietary supplementation of this enzyme is not possible. However, cysteine, which is rate-limiting in the GSH synthesis pathway, crosses both the BBB and most cell membranes. Therefore, cysteine and its derivative N-acetylcysteine have been investigated as a possible dietary supplementation to implement GSH amount, with several clinical trials ongoing (Table 3). Intravenous N-acetylcysteine injection increased blood GSH redox ratios in PD and healthy subjects and magnetic resonance spectroscopy (MRS) showed higher brain GSH concentrations in all subjects. This supports that it is possible to directly monitor GSH levels that could help during clinical trial to determine the activities and the doses of this antioxidant therapy (Holmay et al., 2013).

Another study aimed at assessing the effect of N-acetylcysteine on human embryonic stem cells-derived midbrain dopaminergic neurons treated with rotenone and on PD patients and showed that N-acetylcysteine exposure significantly improved the survival of midbrain dopaminergic neurons treated with rotenone (Monti et al., 2016). Furthermore, Dopamine Transporter scan (DaTscan) analysis on patients treated for 3 months with N-acetylcysteine resulted in increased DAT binding in the caudate and putamen (Monti et al., 2016). These results support a potential direct effect of N-acetylcysteine (Table 3) on the dopamine system in PD patients, but we still ignore whether this compound affects α-Syn nitration state though N-acetylcysteine has shown protective effects against the damage in dopaminergic terminals concomitant with a reduction in α-Syn levels in transgenic mice (Clark et al., 2010).

Coenzime Q10 (CoQ10) is a key component of the electron transport chain that leads to decreased free radical generation, and, in its reduced form, acts as a powerful antioxidant (Shults, 2005). CoQ10 levels were altered in PD cases (Matsubara, 1991; Shults et al., 1997; Molina et al., 2002) with a significant increase in the percentage of oxidized CoQ10 in affected patients (Sohmiya et al., 2004). Numerous studies in in vitro and in vivo models of PD demonstrated that CoQ10 protects neurons against MPTP and rotenone toxicity (Beal, 1998; Horvath et al., 2003; Menke et al., 2003; Sherer et al., 2003; Gille et al., 2004), and 1-Benzyl-1,2,3,4-tetrahydroisoquinol (Shavali et al., 2004; Table 3).

A randomized, double-blind, placebo-controlled, multicenter phase II study in early PD examined the effects of 300, 600, and 1,200 mg per day of CoQ10 vs. placebo. CoQ10 supplementation decreased functional decline in participants and increased platelet mitochondrial complex I and II/III activities. These results suggested a possible disease-modifying effect (Shults and Schapira, 2001). Based on these results, in a phase III study, the group tested whether high doses (1,200 and 2,400 mg/d) of CoQ10 could slow functional decline in early PD. The results showed that CoQ10 could be safely administered to patients with early PD, however no therapeutic efficacy was demonstrated (Parkinson Study Group et al., 2014).

The hydrophilic analogue of CoQ10, idebenone, is well-known antioxidant compound with better pharmacological properties. Clinical safety of idebenone was well described, and the molecule is currently used to treat Freidrich’s ataxia and AD (Orsucci et al., 2011; Montenegro et al., 2018). Two clinical trials assessing the efficacy and safety of idebenone in PD are currently ongoing (Clinical trial identifier: NCT03727295; NCT04152655) and results obtained on PD models are encouraging (Table 3). Indeed, idebenone improved motor coordination and locomotor activity while decreasing TH-positive neurons damage, lipid peroxidation, ferroptosis and other OS markers in rotenone-induced PD models (Avci et al., 2021). Moreover, idebenone activated autophagy and promoted α-Syn degradation by suppressing the AKT/mTOR pathway in SH-SY5Y overexpressing the A53T mutant form of α-Syn (He et al., 2021). This mechanism appears unusual for this compound, but recently idebenone has been demonstrated to act as cytoprotective molecule activating fundamental pathways rather than by functioning as a direct antioxidant agent (Gueven et al., 2021; He et al., 2021).

A new interesting agent for OS modulation is sulforaphane, a phytocompound belonging to the isothiocyanate family and owning lipophilic nature and a molecular size that makes it highly bioavailable (Schepici et al., 2020; Uddin et al., 2020). Its molecular target is nuclear factor erythroid 2 related factor 2 (Nrf2), which is a crucial controller of enzymes involved in antioxidation and detoxification of xenobiotics (Eggler et al., 2008; Zhang et al., 2013; Stefanson and Bakovic, 2014; Sajja et al., 2017). In vitro studies on cellular models of PD treated with sulforaphane showed reduced OS, cell damage and death (Uddin et al., 2020; Table 3). In line with the in vitro studies, in vivo experiments demonstrated that in C57BL/6 mice sulforaphane administration improved motor deficits and counteracted nigrostriatal dopaminergic neurons degeneration and apoptosis attenuating OS and neuroinflammation (Uddin et al., 2020). A phase II clinical trial is currently ongoing to evaluate the efficacy and safety of sulforaphane in PD patients (Clinical trial identifier: NCT05084365).

An interesting molecule to counteract OS is melatonin, a hormone produced endogenously by pineal gland and other tissues. It regulates circadian cycle and also plays a relevant role in neuroprotection, anti-inflammation and anti-oxidation. For all these reasons, it has been considered as a candidate for PD therapy (Table 3). Melatonin is an indoleamine and it can yield electron easily, hence it is a potent reducer agent. It acts as a scavenger for oxygen-and nitrogen-based reactive molecules (Reiter et al., 2002a,b, 2003; Lopez-Burillo et al., 2003; Sudnikovich et al., 2007) and it works as an inhibitor of inducible NO synthase (iNOS; Gilad et al., 1998; Crespo et al., 1999; Dong et al., 2003; Rodriguez et al., 2004, 2007; Lopez et al., 2006). The ability to interact with iNOS and peroxinitrite is the one that makes melatonin a special candidate for the treatment of OS as none of the previous mentioned antioxidant is able to exert this action. It has been demonstrated that melatonin also helps antioxidant enzymes, including SOD and GPx, stimulating the production of GSH (Rodriguez et al., 2004; Reiter et al., 2005; Winiarska et al., 2006). In addition, melatonin has been found to inhibit cyclooxygenase-2 reducing the severity of inflammation (Deng et al., 2006). In particular, it ameliorates inflammation blocking tumor necrosis factor-α (TNF-α; Li and Pelletier, 1995; Reiter et al., 2003) and it impacts on mitochondrial respiration, protecting both proteins of electron transport chain and mitochondrial DNA from oxidative damage (Reiter et al., 2008). Interestingly, melatonin has been found to reduce α-Syn secretion in rat adipose-derived mesenchymal stem cells (Ibrahim et al., 2022). Several phase II and III clinical trials are evaluating the effect of melatonin on sleep disturbances in PD patients (Clinical trial identifiers: NCT02768077; NCT03258294; NCT02789592; NCT02359448; NCT04287543; Table 3). Interestingly, trial NCT04287543 aimed at following the activity of mitochondrial complex I, the levels of MDA and 4-hydroxyalkene and the production of NO among the secondary outcome measures, but it was withdrawn because of COVID-19 pandemic. Other studies on exogenous melatonin investigated the effect of the molecule on rapid eye movement (REM) sleep behavior disorder (RBD), which is a prodromal sign for PD. Among them, the study by Kunz et al. (2004) demonstrated that medical melatonin increased REM sleep percentage to normal levels in patients with reduced REM sleep duration and re-organized REM sleep episode length during night-time sleep. The effect lasted for several weeks after the discontinuation of the therapy. Other studies reported a resolution of clinical RBD symptoms lasting for up to 3 years after discontinuation of melatonin treatment (Kunz and Bes, 1999; Boeve et al., 2001; Kunz et al., 2004).

It is worth considering that unfortunately the limitations offered by OS targeting therapeutic strategies are challenging. Moreover, despite OS is common to several diseases, it rarely constitutes the primary cause of a disease, supporting that the use of an antioxidant may have mild impact on pathology progression. Moreover, in vitro and in vivo evidences demonstrated that endogenous antioxidants support the progression of different types of tumors (Singh et al., 2008; DeNicola et al., 2011; Sayin et al., 2014; George and Abrahamse, 2020; Harris and DeNicola, 2020). This effect is even greater in older people, where the activation of Nrf2 pathway, which usually is chemopreventing, can be deleterious and it could predispose for tumor progression (Forman and Zhang, 2021). Still, all classical antioxidants, excluding melatonin, are potential electron donors and they exhibit both reduced and oxidized forms. In general, these oxidized molecules should be regenerated to the reduce form through a process of recycling that consumes GSH to be exploited or through a redox reaction that, eventually, oxidizes other molecules. This means that the classical antioxidant may act as prooxidant molecules, causing other damages. However, the toxic concentrations of most of these prooxidant regenerated compounds are extremely high and their toxic potential appears negligible.

Another issue is related to the discrepancy that exists in the ratio of in vitro vs. in vivo exogenous agents. In general, in in vitro studies free radicals are produced at much greater rates than what would be observed in real physiological or pathological conditions (Forman et al., 2014). In addition, antioxidant defenses may not be able to reach effective concentrations in vivo. Therefore, it is hard to think that antioxidant approaches may significantly impact on PD progression though we cannot exclude that they may contribute in reducing α-Syn nitration.

6. Acetylation

Protein acetylation is one of the major PTM found in eukaryotes, in which the acetyl group from acetyl coenzyme A is transferred to a specific site on a polypeptide chain. Acetylation is mostly known for the role on gene transcription regulation, indeed through the reversible accumulation of acetylation on the lysines (ac-lys) of the histones, the transcription is activated.

In humans, 80–90% of all proteins become co-translationally acetylated at their N-terminal (Nt) of the nascent polypeptide chains (Arnesen, 2009; Aksnes et al., 2015) in an irreversible way. Nt-acetylation is a general mechanism for stabilizing α-helical structures in both proteins and peptides (Chakrabartty et al., 1993), and makes α-Syn resistant for amyloid aggregation enhancing both protein–protein and protein-membrane interaction (Bartels et al., 2014). Indeed, recent findings indicate that all the in vivo detectable α-Syn is post-translationally modified by an acetyl group attached to the amino group of the first N-terminal amino acid (Anderson et al., 2006; Bartels et al., 2011; Ohrfelt et al., 2011). This modification alters the charge and structure of α-Syn molecules affecting their interaction with lipid membranes, as well as their aggregation process (Bell et al., 2022a,b, 2023). It has been found that ac-lys impacts on α-Syn aggregation (Fauvet et al., 2012; Kang et al., 2012; Gruschus et al., 2013; Bu et al., 2017; de Oliveira et al., 2017) and that acetylated α-Syn and α-tubulin inhibit oligomers formation (Kazantsev and Kolchinsky, 2008). Interestingly, studies demonstrated that increases in histone acetylation are disease-dependently associated with PD progression (Park et al., 2016; Harrison et al., 2018; Toker et al., 2021) and histone-3 or-4 hyperacetylation is a key epigenetic change in dopaminergic neurons exposed to other PD-related neurotoxins. Conversely, the deacetylation of histones operated by histone deacetylase (HDAC) is implicated in the control of α-Syn toxicity. The activity of HDAC6 has been linked with PD pathogenesis (Lemos and Stefanova, 2020) and HDAC6 is highly expressed in LB in PD patients’ brain sections, indicating that HDAC6 may play a key role in the clearance of those misfolded and aggregated protein (Kawaguchi et al., 2003; Du et al., 2010; Richter-Landsberg and Leyk, 2013). Indeed, HDAC6 decreased activity is an essential factor for impaired autophagic flux in PD pathophysiology (Wang et al., 2019). Several studies demonstrated that the inhibitors of HDAC worsen the motor abilities of mice and exacerbate cell death in primary neuron cells (Du et al., 2014), while other demonstrated that HDAC inhibitors restore axonal transport and motor behavior (Godena et al., 2014; Pinho et al., 2016), reduce ROS production, and alleviate dopaminergic neurotoxicity (Jian et al., 2017). Other studies demonstrated the protective effect of pan-HDAC inhibitors such as valproic acid, sodium butyrate, phenylbutyrate, suberoylanilide hydroxamic acid and trichostatin A in in vitro and in vivo models of PD acting through different mechanism listed in Table 4 (Gardian et al., 2004; Chen et al., 2007, 2012; Wu and Guo, 2008; Kidd and Schneider, 2010, 2011; Zhou et al., 2011, 2014; Rane et al., 2012; St Laurent et al., 2013; Harrison et al., 2015; Suo et al., 2015; Sharma et al., 2015a; Kim et al., 2019; Getachew et al., 2020; Hsu et al., 2020). The specific inhibitors of HDAC1, 2 and 3, RGFP109, K560, K-856, MS-275, MC-1568, and LMK235 also showed neuroprotection against α-Syn toxicity (Table 4; Johnston et al., 2013, Formisano et al., 2015, Choong et al., 2016, Hirata et al., 2018, Mazzocchi et al., 2021).

On this line, a recent phase I clinical trial investigated whether phenylbutyrate (Table 4) can increase the removal of α-Syn from the brain into the bloodstream (Clinical trial identifier: NCT02046434), but results are not available yet.

Sirtuins (SIRT) are nicotinamide adenine dinucleotide (NAD⁺)-dependent HDAC, proteins implied in neurodegenerative disorders (Satoh and Imai, 2014). In mammals, there are seven members of the SIRT family: SIRT1-SIRT7. SIRT2 is the most abundant SIRT in the brain and its levels increase with aging (Maxwell et al., 2011). De Oliveira et al. (2017) recently described that SIRT2 interacts with and removes acetyl groups from α-Syn. They also demonstrated both in vitro and in vivo that the inhibition of SIRT2 decreased α-Syn toxicity (Outeiro et al., 2007; de Oliveira et al., 2017).

On the other hand, SIRT1 increases lifespan in mammals (Cohen et al., 2004), promotes mitochondrial biogenesis (Wenz, 2013), protects against neurodegeneration (Kim et al., 2007) and mitigates α-Syn pathology through the induction of the chaperone heat shock protein 70, which prevents the misfolding or clear the aggregates by degradation (Donmez et al., 2012). By reducing signs of aging, the SIRT1-activating drugs, such as resveratrol may have a role in the counteract of neurodegenerative diseases (Barger et al., 2008; Pearson et al., 2008). Indeed, resveratrol and its derivatives are able to alleviate motor and cognitive deficits and neuropathology in different mouse model of PD (Table 4; Guo et al., 2016, Zhang et al., 2018) and to reduce α-Syn toxicity and OS in in vitro models of the pathology (Albani et al., 2009; Arbo et al., 2020; Chau et al., 2021). Interestingly, though the bioavailability and brain penetration of resveratrol are problematic, some modified forms of this molecule have been developed to overcome these issues (Intagliata et al., 2019) and it has been demonstrated that one of the more bioavailable forms of resveratrol acts as a protein aggregation suppressor in vitro and in vivo (Mehringer et al., 2022).

The upstream regulation of SIRT through a replenishment of NAD within the brain has been attempted through the nicotinamide riboside supplementation. Brakedal et al. (2022) summarized the double-blinded, randomized, placebo-controlled phase I study of nicotinamide riboside in which they demonstrated a mild improvement in motor ability and a neuroprotective effect that was previously shown in murine, Drosophila melanogaster and induced pluripotent stem cells-based experimental models of noise induced hearing loss, amyotrophic lateral sclerosis, depression and PD (Table 4; Brown et al., 2014, Sorrentino et al., 2017, Schondorf et al., 2018, Han et al., 2020, Harlan et al., 2020, Xie et al., 2020). Nicotinamide riboside may target multiple processes implicated in the pathophysiology of the disease by upregulating the expression of genes involved in mitochondrial respiration, oxidative damage response, lysosomal and proteasomal function as well as by downregulating inflammatory cytokines in the central nervous system (Canto et al., 2012; Gong et al., 2013; Mehmel et al., 2020; Brakedal et al., 2022). In addition, it is possible that nicotinamide riboside may mitigate epigenomic dysregulation in PD by regulating histone acetylation. Increasing neuronal NAD levels would boost the activity of the NAD-dependent histone deacetylases of the SIRT family, potentially ameliorating histone hyperacetylation in PD.

7. O-GlcNAcylation

O-linked N-acetylglucosamine (O-GlcNAc) is a form of protein glycosylation in which N-acetylglucosamine (GlcNAc) residues are O-linked to ser and threonine (thr) hydroxyl groups of proteins (Butkinaree et al., 2010). The enzymes which control the levels of GlcNAc are O-GlcNAc transferase (OGT) which attaches O-GlcNAc and O-GlcNAcase (OGA), which instead removes the O-GlcNAc (Bond and Hanover, 2013).

O-GlcNAcylation reduces the aggregation propensity and the toxicity of amyloidogenic proteins including and α-Syn (Marotta et al., 2015; Levine et al., 2017; Lewis et al., 2017). α-Syn has several O-GlcNAcylation sites (Cole and Hart, 2001), especially located in the NAC region of the protein (Marotta et al., 2015; Levine et al., 2017, 2019; Lewis et al., 2017). The O-GlcNAcylation at thr72 of α-Syn decreases aggregation propensity and toxicity in cultured cells (Marotta et al., 2015). Moreover, O-GlcNAcylation hampers the cleavage of α-Syn by calpain (Levine et al., 2017), a process involved in the formation of aggregates, and is implicated in the modulation of endocytic and autophagic pathways (Dufty et al., 2007). In addition, it has been demonstrated that pharmacological inhibition or the knockdown of OGA hampers α-Syn pre-formed fibrils internalization (Tavassoly et al., 2021).

Selective inhibitors of OGA are of interest for their potential to reduce the aggregation of the amyloidogenic proteins within brain (Selnick et al., 2019). In this context, thiamet G, a brain permeable molecule, has been shown to increase cerebral O-GlcNAc levels to hamper neurodegeneration and reduce phosphorylation and aggregation of tau (Liu et al., 2004a; Yuzwa et al., 2008; Gong et al., 2012). Moreover, thiamet G improves behavioral features in preclinical models of tauopathies (Yuzwa et al., 2008, 2012, 2014a,b; Yu et al., 2012; Borghgraef et al., 2013; Graham et al., 2014; Hastings et al., 2017). A novel, highly potent and selective OGA inhibitor, MK-8719, has been developed and showing promising results in in vitro and in vivo tauopathies model. The OGA inhibitor ASN120290, that has been recently assigned the Orphan Drug Designation for the treatment of progressive supranuclear palsy (PSP) by the Food and Drug Administration has granted to ASN120290 reduced neurofibrillary tangles in mouse model of tauopathy. Permanne et al. (2022) demonstrated that the administration of ASN120290 enhance α-Syn O-GlcNAcylation and slows the progression of motor impairment in a α-Syn tg mouse model of PD (Table 5). In June 2021, a phase I first-in-human trial assessing the diffusion of ASN121151 to the CNS and the safety and pharmacokinetic profile in elderly healthy and AD subjects has been started (Clinical trial identifier: NCT04759365). Furthermore, a multiple ascending doses PET study is currently ongoing to investigate the brain occupancy of OGA and the pharmacodynamic response in peripheral blood mononuclear cells after repeated doses of ASN121151 to healthy subjects (Clinical trial identifier: NCT05725005; Table 5).

8. Glycation

In the context of sugar-based modifications we can find glycation. Glycation is a non-enzymatic reaction that proceeds under hyperglycemia and during aging. Through the Maillard reaction the reduced carbohydrates and amino compounds form the intermediate Amadori products which in turn break down, thus creating a variety of different carbonyl and dicarbonyl intermediate products, including glyoxal and methylglyoxal (MGO) that are able to bound to the proteins (Hodge, 1955). Lastly, higher molecular weight species or advanced glycation end products (AGEs) can be formed from these lower molecular weight species (Henning and Glomb, 2016). These reactions are generally rather slow and their end products are very stable (Henning and Glomb, 2016). Therefore, short lived proteins are usually not involved in this process, however long-lived proteins, such as α-Syn can be modified in AGEs (Ahmed, 2005; Vicente Miranda and Outeiro, 2010). AGEs colocalize with α-Syn in LB in the SN (Munch et al., 2000) and glycated α-Syn has been identified in brain tissue from PD patients (Vicente Miranda et al., 2017b). MGO reacts with α-Syn to form oligomers, increasing the toxicity (Vicente Miranda et al., 2017b). In addition, diabetes is associated with the accumulation of AGEs (Kopytek et al., 2020) and patients with type 2 diabetes mellitus experience an increased risk to develop PD (Yang et al., 2017; Vaccari et al., 2021), indicating a possible insulin-modulating role in this latter condition. Both diabetes and PD are characterized by altered homeostasis of sugar metabolism (Dunn et al., 2014; Shamsaldeen et al., 2016; Trezzi et al., 2017). Interestingly, antidiabetic drugs have been suggested to exert a neuroprotective role both in PD models and in patients (Konig et al., 2018; Iravanpour et al., 2021). For instance, insulin modulates α-Syn expression and aggregation (Sharma et al., 2015b,c), regulates vesicular monoamine transporter 2 (VMAT2; Kong et al., 2020) and intranasal administration of insulin ameliorated mitochondrial function, motor impairment and dopaminergic neuron death in a rat model of PD (Iravanpour et al., 2021).

Glucagon-like peptide-1 (GLP1) is secreted in response to ingestion and absorption, preferably of carbohydrates and fats (Drucker and Nauck, 2006; Wu et al., 2015; Nauck and Meier, 2018). The binding of GLP1 to its receptor (GLP1R) induces the glucose-dependent pancreatic insulin secretion (Flock et al., 2007; Holst, 2007). It has been demonstrated that agonists (GLP1RA) such as exendin-4 (Ex-4) can regulate several functions related to neurodegeneration, OS and neurogenesis (Kim et al., 2017). Consistently, Ex-4 and derivatives showed beneficial effects in PD animal models (Bertilsson et al., 2008, Rampersaud et al., 2012, Liu et al., 2015, Palleria et al., 2017, Chen et al., 2018, Elbassuoni and Ahmed, 2019, Zhang et al., 2021; Table 6). Indeed, it has been demonstrated that GLP1RA ameliorates MPTP-induced neurotoxicity acting on mitophagy flux, OS and α-Syn aggregation in both the MPTP-mouse model of PD (Lin et al., 2021) and in α-Syn transgenic mice (Yun et al., 2018).

Phase II clinical trials assessing the effect of 12 or 24 months treatments with exenatide, a synthetic Ex-4 derivative, showed cognitive and motor benefits which persisted for 12 months after drug washout in moderate PD patients (Aviles-Olmos et al., 2013, 2014; Table 6). In a next randomized, placebo-controlled, double-blind trial the authors analyzed the improvements of exenatide treated PD patients regarding motor abilities (Athauda et al., 2017), mood and cognition (Athauda et al., 2018). A post hoc analysis showed that younger patients with lower MDS-UPDRS-2 scores and tremor-dominant phenotype had the best response to exenatide (Athauda et al., 2019b). Moreover, there was a positive trend in obese patients or those with insulin resistance (Athauda et al., 2019a). Several other trials are evaluating other GLP1RA such as liraglutide, semaglutide or lixisenatide (Clinical trial identifier: NCT02953665; NCT03659682; NCT03439943; Table 6).

Dipeptidyl peptidase 4 (DDP4) inhibitors such as Vildaglitpin, Saxagliptin, Linaglitptin and Sitaglitpin have also been tested in animals as blockers of peripheral GLP1 degradation (Abdelsalam and Safar, 2015; Nassar et al., 2015; Kabel et al., 2018). In humans DDP4 inhibitors administration showed decrease in PD incidence (Svenningsson et al., 2016; Brauer et al., 2020) and beneficial effect in diabetic PD patients (Jeong et al., 2021; Table 6).

The most common treatment for type 2 diabetes, metformin, showed promising results in MPTP animal models (Katila et al., 2017; Table 6). Moreover, it reduced mitochondrial respiration dysfunction, activating AMP-activated protein kinase (AMPK), which has pro-survival functions and increases α-Syn clearance in animal models of PD (Parekh et al., 2022). Recently, it has been demonstrated that metformin is able to control microglial and astrocyte activation, eventually leading to neuroprotection and controlling dyskinesia development (Ryu et al., 2020). So far, metformin treatments in humans gave rise to conflicting results (Wahlqvist et al., 2012; Ping et al., 2020).

Mitoglitazone, an antidiabetic molecule which was found to protect against MPTP toxicity in cells, rodents and nematodes, reduced the incidence of PD in diabetic patients (Brauer et al., 2015, 2020; Table 6) exerting a better effect when compared to metformin (Brakedal et al., 2017).

Furthermore, high doses of thiamine improved motor function in PD patients by acting on AGE levels (Karachalias et al., 2010; Costantini et al., 2013, 2015; Table 6).

Other molecules showed promising results in preclinical models such as, MGO-scavengers tenilsetam and aminoguanidine that reduced α-Syn aggregation while improving its clearance and motor behavior in a PD models (Vicente Miranda et al., 2017b; Table 6). Telmisartan an anti-hypertension molecule, which was shown to reduce AGEs levels in rodents, demonstrated a protective role in MPTP models (Sato et al., 2014; Table 6).

9. SUMOylation

The covalent addition of a small ubiquitin like modifiers (SUMO) is one of the PTM which characterizes α-Syn. SUMO is a 12 kDa protein attached covalently to the lys-residues of a protein and it is essential for normal cellular processes including cell cycle regulation, nuclear-cytosolic transport, gene transcription, protein stability, response to stress, apoptosis and many others functions (Matunis et al., 1996; Hershko and Ciechanover, 1998).

SUMOylation is mediated by a three-step reaction that involves SUMO activating enzyme (SAE1), Ubc9 conjugating enzyme and SUMO-E3 ligase (Muller et al., 2001; Wilkinson and Henley, 2010). SUMO peptides can be recycled through a process of deSUMOylation by the SUMO proteases from the Ulp/SENP family.

SUMOylation machinery and protein SUMOylation dramatically increase in response to cellular stresses, and so in PD (Zhou et al., 2004; Enserink, 2015). Furthermore, rotenone-injected mice exhibit increased α-Syn and SUMO levels (Weetman et al., 2013). SUMOylation participates in several pathways connected to PD such as regulation of DJ-1 activity, modulation of transcription factors involved in mitochondrial and lysosomal biogenesis, and regulation of mitochondrial fission machinery (Harder et al., 2004; Ariga et al., 2013; Savyon and Engelender, 2020).

SUMO has been shown to enhance the solubility of aggregation-prone proteins like α-Syn, and impaired SUMOylation increased α-Syn aggregation and toxicity in HEK293 cells and a PD rat models (Krumova et al., 2011). On the other hand, SUMOylation competes with ubiquitination on the same lys residue, protecting the protein from degradation (Rott et al., 2017; Rousseaux et al., 2018). The discrepancies seen on α-Syn aggregation may be related to the different SUMO isoforms and SUMO-ligases that may be involved in the processes (Tatham et al., 2001; Bohren et al., 2004; Wilkinson and Henley, 2010).

The only tested molecule for the interference with E1-SUMO complex formation in PD like model, is ginkgolic acid (Fukuda et al., 2009; Table 7), which decreases the levels of SUMOylation stimulating the macroautophagic clearance of α-Syn aggregates (Vijayakumaran et al., 2019).

So far, SUMOylation targeting has been achieved especially in oncology, indeed spectomycin B1 had been proposed as therapeutic agent to cure breast cancer through the blocking of SUMOylation preventing the formation of the Ubc9-SUMO (Hirohama et al., 2013). In addition, the potent SAE inhibitor ML-792 impairs SUMO conjugation but also induces significant loss of viability in multiple cancer cell lines (He et al., 2017). On the other hand, global cellular SUMOylation is enhanced in response to interferons (Maroui et al., 2018).

10. Ubiquitination

The ubiquitin–proteasome system (UPS) mediates the degradation of proteins in mammalian cells (Ross and Pickart, 2004). The addition of multiple molecules of ubiquitin, a conserved 8.5-kDa polypeptide, constitute the signal for proteasome-mediated degradation. Ubiquitin–substrate ligation is mediated by different enzymatic steps which are mainly mediated by E3 ligases. These latter recognize specific substrate-based signals in a manner that is frequently regulated by covalent modification (Weissman, 2001), in which the first ubiquitin is covalently joined to proteins through an isopeptide bond between the C-terminus of ubiquitin and a lys residue, and must be proteolytically processed by ubiquitin C-terminal hydrolases (UCHs) before it can acquire activity (Weissman, 2001). Additional ubiquitins are then linked to the first one to form a polyubiquitin chain that is a potent attractive signal for the regulatory complex of the proteasome. The UPS is vitally important for protecting cells against the toxic effects of misfolded proteins (Engelender et al., 2022). The 26S proteasome consists of more than 60 subunits. It is composed by: (1) a central, barrel-shaped catalytic (20S) complex carrying multiple active sites, which are sequestered in an interior chamber that is only accessible through a narrow axial pore; (2) two distally positioned regulatory (19S) complexes which unfold the substrate polypeptide chain and translocate it through this pore and into the active-site chamber, using integral chaperone subunits placed immediately adjacent to the axial pore of the 20S complex (Ross and Pickart, 2004). Of note, studies in the post-mortem brains of sporadic PD patients showed that LB contain ubiquitinated α-Syn that is not associated with UPS impairment (Tofaris et al., 2003). However, even non-ubiquitinated α-Syn appears to be degraded by the 20S proteasome (Tofaris et al., 2001), supporting the occurrence of ubiquitin-independent mechanism of UPS-mediated α-Syn degradation in synucleinopathies.

Studies in cell models or purified systems led to conflicting results either supporting that both 20S and 26S proteasomes degrade α-Syn or failing to detect α-Syn accumulation upon UPS inhibition (Bennett et al., 1999; Tofaris et al., 2001, 2011; Webb et al., 2003; Emmanouilidou et al., 2010; Shabek et al., 2012) hinting that the UPS may play a relevant role in degrading a fraction of α-Syn, whose relative abundance may vary between cell types and experimental conditions (Stefanis et al., 2019).

Promoting the activity of the UPS can thus be considered as a possible therapeutic strategy for combating α-Syn accumulation (Engelender et al., 2022; Table 8). For instance, following evidence that p38 mitogen-activated protein kinase (MAPK) negatively regulates proteasome activity, the p38 MAPK inhibitor PD169316 has been identified as a proteasome activator that decreases α-Syn toxicity in cells (Braun et al., 2021; Engelender et al., 2022). Several p38 MAPK inhibitors tested in clinical trials for chronic inflammatory diseases and cancer may also be considered as possible UPS stimulators, though their neuroprotective effects may not be solely ascribed to UPS induction. Indeed, studies in experimental models of synucleinopathies and of other neurodegenerative diseases such as AD have shown that p38 MAPK plays a relevant role in mediating other key processes involved in neurodegeneration, neuroinflammation and disease protein-mediated brain damage (Giovannini et al., 2002, 2008; Cuenda and Rousseau, 2007).

Alternatively, compounds that work as gate-openers of the 20S proteasome by preventing the barrel closing may also promote α-Syn clearing (Forster and Hill, 2003; Jones et al., 2017). For instance, chlorpromazine and some derivatives devoid of dopamine receptors D2 binding were shown to promote the degradation of α-Syn by interacting with the 20S subunits and preventing its closure (Jones et al., 2017).

Another strategy to increase proteasomal activity is to modulate the phosphorylation status of its subunits that are influenced by several protein kinases (Kors et al., 2019). In particular, cAMP-dependent protein kinase A (PKA) phosphorylates the 19S subunits Rpt6 and Rpn6, leading to activation of 20S proteolytic activities in a process that may involve changes in proteasomal conformation (Zhang et al., 2007; Lokireddy et al., 2015). Despite the benefits of PKA activators, no positive outcome on improving cognition has been observed in clinical trials with forskolin analogs (Sanders and Rajagopal, 2020). On the other hand, several clinical trials assessing the efficacy of phosphodiesterase inhibitors are currently under way, including rolipram, cilostazol and vinpocetine (Prickaerts et al., 2017) and may hold promise for treating synucleinopathies.

A more recent approach to promote the proteasomal degradation of disease proteins is cell-penetrating peptides that specifically interact with the target protein and the proteasome. One promising peptide consists of a portion of β-synuclein peptide that interacts with α-Syn, which was fused to the cell-penetrating peptide TAT and a proteasomal degron and significantly decreased the neuronal levels of α-Syn via proteasome as well as neurotoxicity in mice (Jin et al., 2021).

Finally, the proteasomal degradation of disease proteins can also be improved Proteolysis Targeting Chimeric (PROTAC) compounds (Sakamoto et al., 2001). The technology relies on the fusion of a ligand for the target protein to a ligand for an E3 ubiquitin-ligase, such as cereblon and Van Hippel-Landau (VHL; Au et al., 2020). α-Syn-targeting PROTAC are currently in preclinical development (Kargbo, 2020).

11. Discussion

The evidence summarized in this review highlights the relevance of α-Syn PTMs in PD pathophysiology. In the last few years, α-Syn PTMs have been investigated as biomarker for the diagnosis and progression of PD and other synucleinopathies. Moreover, studies supporting that PTMs control structural changes in α-Syn thus influencing its aggregation propensity, have blossomed great interest for the development of innovative therapeutic strategies, that by modulating α-Syn PTM, could reduce its pathological aggregation or spreading. Interestingly, some novel therapeutic strategies modulating α-Syn PTMs are already under investigation in clinical trials. This notwithstanding, further studies are warranted to better clarify the role of PTMs on α-Syn pathophysiology, to confirm the translational potential of PTMs-modifying drugs in synucleinopathies as well as to disclose whether the evaluation of α-Syn PTMs in peripheral tissues can be a valuable readout to monitor the effect of such approaches.

Funding

We are grateful to the Michael J. Fox Foundation for Parkinson’s Research, NY, USA (grant ID: MJFF-021179), the Multiple system atrophy coalition, USA, and the MIUR PRIN 2017-1065.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1

  AbbottR. D.RossG. W.PetrovitchH.TannerC. M.DavisD. G.MasakiK. H.et al. (2007). Bowel movement frequency in late-life and incidental Lewy bodies. Mov. Disord.22, 1581–1586. doi: 10.1002/mds.21560

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  Abd-ElhadiS.HonigA.Simhi-HahamD.SchechterM.LinetskyE.Ben-HurT.et al. (2015). Total and proteinase K-resistant alpha-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson's disease. Sci. Rep.5:11120. doi: 10.1038/srep11120

  • CrossRef
  • Google Scholar

• 3

  Abd ElhadiS.GrigolettoJ.PoliM.ArosioP.ArkadirD.SharonR. (2019). Alpha-synuclein in blood cells differentiates Parkinson's disease from healthy controls. Ann. Clin. Transl. Neurol.6, 2426–2436. doi: 10.1002/acn3.50944

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  AbdelsalamR. M.SafarM. M. (2015). Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways. J. Neurochem.133, 700–707. doi: 10.1111/jnc.13087

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  Abou-SleimanP. M.MuqitM. M.WoodN. W. (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci.7, 207–219. doi: 10.1038/nrn1868

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  AhmedN. (2005). Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res. Clin. Pract.67, 3–21. doi: 10.1016/j.diabres.2004.09.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  AhnB. H.RhimH.KimS. Y.SungY. M.LeeM. Y.ChoiJ. Y.et al. (2002). Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J. Biol. Chem.277, 12334–12342. doi: 10.1074/jbc.M110414200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  AksnesH.HoleK.ArnesenT. (2015). Molecular, cellular, and physiological significance of N-terminal acetylation. Int. Rev. Cell Mol. Biol.316, 267–305. doi: 10.1016/bs.ircmb.2015.01.001

  • CrossRef
  • Google Scholar

• 9

  AlamZ. I.JennerA.DanielS. E.LeesA. J.CairnsN.MarsdenC. D.et al. (1997). Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem.69, 1196–1203. doi: 10.1046/j.1471-4159.1997.69031196.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  AlbaniD.PolitoL.BatelliS.De MauroS.FracassoC.MartelliG.et al. (2009). The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem.110, 1445–1456. doi: 10.1111/j.1471-4159.2009.06228.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  Alegre-AbarrateguiJ.AnsorgeO.EsiriM.Wade-MartinsR. (2008). LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol.34, 272–283. doi: 10.1111/j.1365-2990.2007.00888.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  AndersonJ. P.WalkerD. E.GoldsteinJ. M.De LaatR.BanducciK.CaccavelloR. J.et al. (2006). Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem.281, 29739–29752. doi: 10.1074/jbc.M600933200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  AntelopeO.VelloreN. A.PomicterA. D.PatelA. B.Van ScoykA.ClairP. M.et al. (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp. Hematol.77, 36–40.e2. doi: 10.1016/j.exphem.2019.08.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  ArawakaS.WadaM.GotoS.KarubeH.SakamotoM.RenC. H.et al. (2006). The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci.26, 9227–9238. doi: 10.1523/JNEUROSCI.0341-06.2006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  ArboB. D.Andre-MiralC.Nasre-NasserR. G.SchimithL. E.SantosM. G.Costa-SilvaD.et al. (2020). Resveratrol derivatives as potential treatments for Alzheimer's and Parkinson's disease. Front. Aging Neurosci.12:103. doi: 10.3389/fnagi.2020.00103

  • CrossRef
  • Google Scholar

• 16

  ArigaH.Takahashi-NikiK.KatoI.MaitaH.NikiT.Iguchi-ArigaS. M. (2013). Neuroprotective function of DJ-1 in Parkinson's disease. Oxidative Med. Cell. Longev.2013:683920. doi: 10.1155/2013/683920

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  ArnesenT. (2009). Protein N-terminal acetylation: NAT 2007-2008 Symposia. BMC Proc.3:S1. doi: 10.1186/1753-6561-3-S6-S1

  • CrossRef
  • Google Scholar

• 18

  AthaudaD.GulyaniS.KarnatiH. K.LiY.TweedieD.MustapicM.et al. (2019a). Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol.76, 420–429. doi: 10.1001/jamaneurol.2018.4304

  • CrossRef
  • Google Scholar

• 19

  AthaudaD.MaclaganK.BudnikN.ZampedriL.HibbertS.Aviles-OlmosI.et al. (2019b). Post hoc analysis of the exenatide-PD trial-factors that predict response. Eur. J. Neurosci.49, 410–421. doi: 10.1111/ejn.14096

  • CrossRef
  • Google Scholar

• 20

  AthaudaD.MaclaganK.BudnikN.ZampedriL.HibbertS.SkeneS. S.et al. (2018). What effects might exenatide have on non-motor symptoms in Parkinson's disease: a post hoc analysis. J. Parkinsons Dis.8, 247–258. doi: 10.3233/JPD-181329

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  AthaudaD.MaclaganK.SkeneS. S.Bajwa-JosephM.LetchfordD.ChowdhuryK.et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet390, 1664–1675. doi: 10.1016/S0140-6736(17)31585-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  AuY. Z.WangT.SiguaL. H.QiJ. (2020). Peptide-based PROTAC: the predator of pathological proteins. Cell Chem. Biol.27, 637–639. doi: 10.1016/j.chembiol.2020.06.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  AvciB.GunaydinC.GuvencT.YavuzC. K.KurucaN.BilgeS. S. (2021). Idebenone ameliorates rotenone-induced Parkinson's disease in rats through decreasing lipid peroxidation. Neurochem. Res.46, 513–522. doi: 10.1007/s11064-020-03186-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  Aviles-OlmosI.DicksonJ.KefalopoulouZ.DjamshidianA.EllP.SoderlundT.et al. (2013). Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest.123, 2730–2736. doi: 10.1172/JCI68295

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  Aviles-OlmosI.DicksonJ.KefalopoulouZ.DjamshidianA.KahanJ.EllP.et al. (2014). Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis.4, 337–344. doi: 10.3233/JPD-140364

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  BabaM.NakajoS.TuP. H.TomitaT.NakayaK.LeeV. M.et al. (1998). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol.152, 879–884. PMID:

  • Pubmed Abstract
  • Google Scholar

• 27

  BakerM. G.GrahamL. (2004). The journey: Parkinson's disease. BMJ329, 611–614. doi: 10.1136/bmj.329.7466.611

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  BakhitY.SchmittI.HamedA.IbrahimE. A. A.MohamedI. N.El-SadigS. M.et al. (2022). Methylation of alpha-synuclein in a Sudanese cohort. Parkinsonism Relat. Disord.101, 6–8. doi: 10.1016/j.parkreldis.2022.05.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  BargerJ. L.KayoT.VannJ. M.AriasE. B.WangJ.HackerT. A.et al. (2008). A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One3:e2264. doi: 10.1371/annotation/c54ef754-1962-4125-bf19-76d3ec6f19e5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  BartelsT.ChoiJ. G.SelkoeD. J. (2011). Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature477, 107–110. doi: 10.1038/nature10324

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  BartelsT.KimN. C.LuthE. S.SelkoeD. J. (2014). N-alpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One9:e103727. doi: 10.1371/journal.pone.0103727

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  BeachT. G.AdlerC. H.SueL. I.VeddersL.LueL.White IiiC. L.et al. (2010). Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol.119, 689–702. doi: 10.1007/s00401-010-0664-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  BealM. F. (1998). Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol.44, S110–S114. doi: 10.1002/ana.410440716

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  BeardJ. L.ConnorJ. R. (2003). Iron status and neural functioning. Annu. Rev. Nutr.23, 41–58. doi: 10.1146/annurev.nutr.23.020102.075739

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  BellR.Castellana-CruzM.NeneA.ThrushR. J.XuC. K.KumitaJ. R.et al. (2022a). Effects of N-terminal acetylation on the aggregation of disease-related alpha-synuclein variants. J. Mol. Biol.167825

  • Google Scholar

• 36

  BellR.Castellana-CruzM.NeneA.ThrushR. J.XuC. K.KumitaJ. R.et al. (2023). Effects of N-terminal acetylation on the aggregation of disease-related alpha-synuclein variants. J. Mol. Biol.435:167825. doi: 10.1016/j.jmb.2022.167825

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  BellR.ThrushR. J.Castellana-CruzM.OellerM.StaatsR.NeneA.et al. (2022b). N-terminal acetylation of alpha-synuclein slows down its aggregation process and alters the morphology of the resulting aggregates. Biochemistry61, 1743–1756. doi: 10.1021/acs.biochem.2c00104

  • CrossRef
  • Google Scholar

• 38

  BellR.VendruscoloM. (2021). Modulation of the interactions between alpha-synuclein and lipid membranes by Post-translational modifications. Front. Neurol.12:661117. doi: 10.3389/fneur.2021.661117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  BellucciA.AntoniniA.PizziM.SpanoP. (2017). The end is the beginning: Parkinson's disease in the light of brain imaging. Front. Aging Neurosci.9:330. doi: 10.3389/fnagi.2017.00330

  • CrossRef
  • Google Scholar

• 40

  BellucciA.MercuriN. B.VenneriA.FaustiniG.LonghenaF.PizziM.et al. (2016). Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathol. Appl. Neurobiol.42, 77–94. doi: 10.1111/nan.12297

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  BellucciA.NavarriaL.ZaltieriM.MissaleC.SpanoP. (2012). Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res.1432, 95–113. doi: 10.1016/j.brainres.2011.11.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  BennettM. C.BishopJ. F.LengY.ChockP. B.ChaseT. N.MouradianM. M. (1999). Degradation of alpha-synuclein by proteasome. J. Biol. Chem.274, 33855–33858. doi: 10.1074/jbc.274.48.33855

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  BertilssonG.PatroneC.ZachrissonO.AnderssonA.DannaeusK.HeidrichJ.et al. (2008). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res.86, 326–338. doi: 10.1002/jnr.21483

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  BoeveB. F.SilberM. H.FermanT. J.LucasJ. A.ParisiJ. E. (2001). Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16, 622–630. doi: 10.1002/mds.1120

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  BohrenK. M.NadkarniV.SongJ. H.GabbayK. H.OwerbachD. (2004). A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem.279, 27233–27238. doi: 10.1074/jbc.M402273200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  BondM. R.HanoverJ. A. (2013). O-GlcNAc cycling: a link between metabolism and chronic disease. Annu. Rev. Nutr.33, 205–229. doi: 10.1146/annurev-nutr-071812-161240

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  BorghgraefP.MenuetC.TheunisC.LouisJ. V.DevijverH.MaurinH.et al. (2013). Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One8:e84442. doi: 10.1371/journal.pone.0084442

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48

  BougeaA.KorosC.StefanisL. (2019a). Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. J. Neural Transm. (Vienna)126, 1373–1382. doi: 10.1007/s00702-019-02062-4

  • CrossRef
  • Google Scholar

• 49

  BougeaA.StefanisL.ParaskevasG. P.EmmanouilidouE.VekrelisK.KapakiE. (2019b). Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. Neurol. Sci.40, 929–938. doi: 10.1007/s10072-019-03738-1

  • CrossRef
  • Google Scholar

• 50

  BrahmachariS.GeP.LeeS. H.KimD.KaruppagounderS. S.KumarM.et al. (2016). Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration. J. Clin. Invest.126, 2970–2988. doi: 10.1172/JCI85456

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  BrakedalB.DolleC.RiemerF.MaY.NidoG. S.SkeieG. O.et al. (2022). The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab.34:e6. doi: 10.1016/j.cmet.2022.02.001

  • CrossRef
  • Google Scholar

• 52

  BrakedalB.FlonesI.ReiterS. F.TorkildsenO.DolleC.AssmusJ.et al. (2017). Glitazone use associated with reduced risk of Parkinson's disease. Mov. Disord.32, 1594–1599. doi: 10.1002/mds.27128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  BrasherB. B.Van EttenR. A. (2000). c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem.275, 35631–35637. doi: 10.1074/jbc.M005401200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  BrauerR.BhaskaranK.ChaturvediN.DexterD. T.SmeethL.DouglasI. (2015). Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med.12:e1001854. doi: 10.1371/journal.pmed.1001854

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  BrauerR.WeiL.MaT.AthaudaD.GirgesC.VijiaratnamN.et al. (2020). Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. Brain143, 3067–3076. doi: 10.1093/brain/awaa262

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  BraunA. R.LiaoE. E.HorvathM.KalraP.AcostaK.YoungM. C.et al. (2021). Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors. NPJ Parkinsons Dis.7:52. doi: 10.1038/s41531-021-00195-6

  • CrossRef
  • Google Scholar

• 57

  BrownD. R. (2007). Interactions between metals and alpha-synuclein--function or artefact?FEBS J.274, 3766–3774. doi: 10.1111/j.1742-4658.2007.05917.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  BrownK. D.MaqsoodS.HuangJ. Y.PanY.HarkcomW.LiW.et al. (2014). Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab.20, 1059–1068. doi: 10.1016/j.cmet.2014.11.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  BuB.TongX.LiD.HuY.HeW.ZhaoC.et al. (2017). N-terminal acetylation preserves alpha-Synuclein from Oligomerization by blocking intermolecular hydrogen bonds. ACS Chem. Neurosci.8, 2145–2151. doi: 10.1021/acschemneuro.7b00250

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  BurreJ.SharmaM.TsetsenisT.BuchmanV.EthertonM. R.SudhofT. C. (2010). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science329, 1663–1667. doi: 10.1126/science.1195227

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  ButkinareeC.ParkK.HartG. W. (2010). O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta1800, 96–106. doi: 10.1016/j.bbagen.2009.07.018

  • CrossRef
  • Google Scholar

• 62

  CalabresiP.MechelliA.NataleG.Volpicelli-DaleyL.Di LazzaroG.GhiglieriV. (2023). Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis.14:176. doi: 10.1038/s41419-023-05672-9

  • CrossRef
  • Google Scholar

• 63

  CampbellB. C.McleanC. A.CulvenorJ. G.GaiW. P.BlumbergsP. C.JakalaP.et al. (2001). The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem.76, 87–96. doi: 10.1046/j.1471-4159.2001.00021.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  CantoC.HoutkooperR. H.PirinenE.YounD. Y.OosterveerM. H.CenY.et al. (2012). The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab.15, 838–847. doi: 10.1016/j.cmet.2012.04.022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  CarboniE.TatenhorstL.TongesL.BarskiE.DambeckV.BahrM.et al. (2017). Deferiprone rescues behavioral deficits induced by mild Iron exposure in a mouse model of alpha-synuclein aggregation. NeuroMolecular Med.19, 309–321. doi: 10.1007/s12017-017-8447-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  CariuloC.MartufiP.VeraniM.AzzolliniL.BruniG.WeissA.et al. (2019). Phospho-S129 alpha-synuclein is present in human plasma but not in cerebrospinal fluid as determined by an ultrasensitive immunoassay. Front. Neurosci.13:889. doi: 10.3389/fnins.2019.00889

  • CrossRef
  • Google Scholar

• 67

  ChakrabarttyA.DoigA. J.BaldwinR. L. (1993). Helix capping propensities in peptides parallel those in proteins. Proc. Natl. Acad. Sci. U. S. A.90, 11332–11336. doi: 10.1073/pnas.90.23.11332

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  ChanC. S.GuzmanJ. N.IlijicE.MercerJ. N.RickC.TkatchT.et al. (2007). Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature447, 1081–1086. doi: 10.1038/nature05865

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  ChauE.KimH.ShinJ.MartinezA.KimJ. R. (2021). Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative. Biochem. Biophys. Res. Commun.574, 85–90. doi: 10.1016/j.bbrc.2021.08.049

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  ChavarriaC.SouzaJ. M. (2013). Oxidation and nitration of alpha-synuclein and their implications in neurodegenerative diseases. Arch. Biochem. Biophys.533, 25–32. doi: 10.1016/j.abb.2013.02.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  ChenL.PeriquetM.WangX.NegroA.McleanP. J.HymanB. T.et al. (2009). Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Investig.119, 3257–3265. doi: 10.1172/JCI39088

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  ChenP. S.WangC. C.BortnerC. D.PengG. S.WuX.PangH.et al. (2007). Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience149, 203–212. doi: 10.1016/j.neuroscience.2007.06.053

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  ChenS.YuS. J.LiY.LeccaD.GlotfeltyE.KimH. K.et al. (2018). Author correction: post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Sci. Rep.8:13953. doi: 10.1038/s41598-018-31455-w

  • CrossRef
  • Google Scholar

• 74

  ChenS. H.WuH. M.OssolaB.SchendzielorzN.WilsonB. C.ChuC. H.et al. (2012). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol.165, 494–505. doi: 10.1111/j.1476-5381.2011.01575.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  ChintaS. J.MallajosyulaJ. K.RaneA.AndersenJ. K. (2010). Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett.486, 235–239. doi: 10.1016/j.neulet.2010.09.061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  ChoiB. K.ChoiM. G.KimJ. Y.YangY.LaiY.KweonD. H.et al. (2013). Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U. S. A.110, 4087–4092. doi: 10.1073/pnas.1218424110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  ChoongC. J.SasakiT.HayakawaH.YasudaT.BabaK.HirataY.et al. (2016). A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease. Neurobiol. Aging37, 103–116. doi: 10.1016/j.neurobiolaging.2015.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  ChungS. J.KimJ.LeeH. J.RyuH. S.KimK.LeeJ. H.et al. (2016). Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: limited role as a biomarker. Mov. Disord.31, 241–249. doi: 10.1002/mds.26473

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  ClarkJ.CloreE. L.ZhengK.AdameA.MasliahE.SimonD. K. (2010). Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One5:e12333. doi: 10.1371/journal.pone.0012333

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  ClaytonD. F.GeorgeJ. M. (1998). The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci.21, 249–254. doi: 10.1016/S0166-2236(97)01213-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  CohenH. Y.MillerC.BittermanK. J.WallN. R.HekkingB.KesslerB.et al. (2004). Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science305, 390–392. doi: 10.1021/acschembio.8b00466

  • CrossRef
  • Google Scholar

• 82

  ColeR. N.HartG. W. (2001). Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem.79, 1080–1089. doi: 10.1046/j.1471-4159.2001.00655.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  CostantiniA.PalaM. I.CompagnoniL.ColangeliM. (2013). High-dose thiamine as initial treatment for Parkinson's disease. BMJ Case Rep.2013:bcr2013009289. doi: 10.1136/bcr-2013-009289

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  CostantiniA.PalaM. I.GrossiE.MondonicoS.CardelliL. E.JennerC.et al. (2015). Long-term treatment with high-dose thiamine in Parkinson disease: an open-label pilot study. J. Altern. Complement. Med.21, 740–747. doi: 10.1089/acm.2014.0353

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  CrespoE.MaciasM.PozoD.EscamesG.MartinM.VivesF.et al. (1999). Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J.13, 1537–1546. doi: 10.1096/fasebj.13.12.1537

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  CrowtherR. A.JakesR.SpillantiniM. G.GoedertM. (1998). Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett.436, 309–312. doi: 10.1016/S0014-5793(98)01146-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  CuendaA.RousseauS. (2007). p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta1773, 1358–1375. doi: 10.1016/j.bbamcr.2007.03.010

  • CrossRef
  • Google Scholar

• 88

  DanielsonS. R.HeldJ. M.SchillingB.OoM.GibsonB. W.AndersenJ. K. (2009). Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal. Chem.81, 7823–7828. doi: 10.1021/ac901176t

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  DauerW.KholodilovN.VilaM.TrillatA. C.GoodchildR.LarsenK. E.et al. (2002). Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A.99, 14524–14529. doi: 10.1073/pnas.172514599

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  De BartoloM. I.VivacquaG.BelvisiD.MancinelliR.FabbriniA.ManzoN.et al. (2023). A combined panel of salivary biomarkers in de novo Parkinson's disease. Ann. Neurol.93, 446–459. doi: 10.1002/ana.26550

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  De OliveiraR. M.Vicente MirandaH.FrancelleL.PinhoR.SzegoE. M.MartinhoR.et al. (2017). Correction: the mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol.15:e1002601. doi: 10.1371/journal.pbio.1002601

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  De RijkM. C.BretelerM. M.Den BreeijenJ. H.LaunerL. J.GrobbeeD. E.Van Der MecheF. G.et al. (1997). Dietary antioxidants and Parkinson disease. The rotterdam study. Arch. Neurol.54, 762–765. doi: 10.1001/archneur.1997.00550180070015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  DecressacM.MattssonB.LundbladM.WeikopP.BjorklundA. (2012). Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol. Dis.45, 939–953. doi: 10.1016/j.nbd.2011.12.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  DengW. G.TangS. T.TsengH. P.WuK. K. (2006). Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood108, 518–524. doi: 10.1182/blood-2005-09-3691

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  DenicolaG. M.KarrethF. A.HumptonT. J.GopinathanA.WeiC.FreseK.et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature475, 106–109. doi: 10.1038/nature10189

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  DevicI.HwangH.EdgarJ. S.IzutsuK.PreslandR.PanC.et al. (2011). Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain134:e178. doi: 10.1093/brain/awr015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  DevosD.LabreucheJ.RascolO.CorvolJ. C.DuhamelA.Guyon DelannoyP.et al. (2022). Trial of Deferiprone in Parkinson's Disease. N. Engl. J. Med.387, 2045–2055. doi: 10.1056/NEJMoa2209254

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  Di MaioR.BarrettP. J.HoffmanE. K.BarrettC. W.ZharikovA.BorahA.et al. (2016). Alpha-synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci. Transl. Med.8:342ra78. doi: 10.1126/scitranslmed.aaf3634

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  DikiyI.FauvetB.JovicicA.Mahul-MellierA. L.DesobryC.El-TurkF.et al. (2016). Semisynthetic and in vitro phosphorylation of alpha-synuclein at Y39 promotes functional partly helical membrane-bound states resembling those induced by PD mutations. ACS Chem. Biol.11, 2428–2437. doi: 10.1021/acschembio.6b00539

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  DonadioV.IncensiA.El-AgnafO.RizzoG.VaikathN.Del SorboF.et al. (2018). Skin alpha-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. Sci. Rep.8:14246. doi: 10.1038/s41598-018-32588-8

  • CrossRef
  • Google Scholar

• 101

  DonadioV.IncensiA.LetaV.GiannoccaroM. P.ScaglioneC.MartinelliP.et al. (2014). Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology82, 1362–1369. doi: 10.1212/WNL.0000000000000316

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  DongW. G.MeiQ.YuJ. P.XuJ. M.XiangL.XuY. (2003). Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol.9, 1307–1311. doi: 10.3748/wjg.v9.i6.1307

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  DonmezG.ArunA.ChungC. Y.McleanP. J.LindquistS.GuarenteL. (2012). SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J. Neurosci.32, 124–132. doi: 10.1523/JNEUROSCI.3442-11.2012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  DruckerD. J.NauckM. A. (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet368, 1696–1705. doi: 10.1016/S0140-6736(06)69705-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  DuG.LiuX.ChenX.SongM.YanY.JiaoR.et al. (2010). Drosophila histone deacetylase 6 protects dopaminergic neurons against alpha-synuclein toxicity by promoting inclusion formation. Mol. Biol. Cell21, 2128–2137. doi: 10.1091/mbc.e10-03-0200

  • CrossRef
  • Google Scholar

• 106

  DuY.WangF.ZouJ.LeW.DongQ.WangZ.et al. (2014). Histone deacetylase 6 regulates cytotoxic alpha-synuclein accumulation through induction of the heat shock response. Neurobiol. Aging35, 2316–2328. doi: 10.1016/j.neurobiolaging.2014.04.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  DuftyB. M.WarnerL. R.HouS. T.JiangS. X.Gomez-IslaT.LeenhoutsK. M.et al. (2007). Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol.170, 1725–1738. doi: 10.2353/ajpath.2007.061232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  DunnL.AllenG. F.MamaisA.LingH.LiA.DuberleyK. E.et al. (2014). Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiol. Aging35, 1111–1115. doi: 10.1016/j.neurobiolaging.2013.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  EgglerA. L.GayK. A.MesecarA. D. (2008). Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol. Nutr. Food Res.52, S84–S94. doi: 10.1002/mnfr.200700249

  • CrossRef
  • Google Scholar

• 110

  EidR.ArabN. T.GreenwoodM. T. (2017). Iron mediated toxicity and programmed cell death: a review and a re-examination of existing paradigms. Biochim. Biophys. Acta, Mol. Cell Res.1864, 399–430. doi: 10.1016/j.bbamcr.2016.12.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  El-AgnafO. M.BodlesA. M.GuthrieD. J.HarriottP.IrvineG. B. (1998a). The N-terminal region of non-a beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur. J. Biochem.258, 157–163.

  • Google Scholar

• 112

  El-AgnafO. M.JakesR.CurranM. D.MiddletonD.IngenitoR.BianchiE.et al. (1998b). Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett.440, 71–75.

  • Google Scholar

• 113

  ElbassuoniE. A.AhmedR. F. (2019). Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes. Neurochem. Int.131:104583. doi: 10.1016/j.neuint.2019.104583

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  EllisC. E.MurphyE. J.MitchellD. C.GolovkoM. Y.ScagliaF.Barcelo-CoblijnG. C.et al. (2005). Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell. Biol.25, 10190–10201. doi: 10.1128/MCB.25.22.10190-10201.2005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  EllisC. E.SchwartzbergP. L.GriderT. L.FinkD. W.NussbaumR. L. (2001). Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem.276, 3879–3884. doi: 10.1074/jbc.M010316200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  EmmanouilidouE.StefanisL.VekrellisK. (2010). Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging31, 953–968. doi: 10.1016/j.neurobiolaging.2008.07.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  EngelenderS.IsacsonO. (2017). The threshold theory for Parkinson's Disease. Trends Neurosci.40, 4–14. doi: 10.1016/j.tins.2016.10.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  EngelenderS.StefanisL.OddoS.BellucciA. (2022). Can we treat neurodegenerative Proteinopathies by enhancing protein degradation?Mov. Disord.37, 1346–1359. doi: 10.1002/mds.29058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  EnserinkJ. M. (2015). Sumo and the cellular stress response. Cell Div10:4. doi: 10.1186/s13008-015-0010-1

  • CrossRef
  • Google Scholar

• 120

  EtminanM.GillS. S.SamiiA. (2005). Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol.4, 362–365. doi: 10.1016/S1474-4422(05)70097-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  FaustiniG.LonghenaF.VaranitaT.BubaccoL.PizziM.MissaleC.et al. (2018). Synapsin III deficiency hampers alpha-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Acta Neuropathol.136, 621–639. doi: 10.1007/s00401-018-1892-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  FaustiniG.MarchesanE.ZontaL.BonoF.BottaniE.LonghenaF.et al. (2019). Alpha-Synuclein preserves mitochondrial fusion and function in neuronal cells. Oxidative Med. Cell. Longev.2019:4246350. doi: 10.1155/2019/4246350

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  FauvetB.FaresM. B.SamuelF.DikiyI.TandonA.EliezerD.et al. (2012). Characterization of semisynthetic and naturally Nalpha-acetylated alpha-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of alpha-synuclein. J. Biol. Chem.287, 28243–28262. doi: 10.1074/jbc.M112.383711

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  FayyadM.SalimS.MajbourN.ErskineD.StoopsE.MollenhauerB.et al. (2019). Parkinson's disease biomarkers based on alpha-synuclein. J. Neurochem.150, 626–636. doi: 10.1111/jnc.14809

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  FeanyM. B.BenderW. W. (2000). A Drosophila model of Parkinson's disease. Nature404, 394–398. doi: 10.1038/35006074

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  FenyiA.Leclair-VisonneauL.ClairembaultT.CoronE.NeunlistM.MelkiR.et al. (2019). Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification. Neurobiol. Dis.129, 38–43. doi: 10.1016/j.nbd.2019.05.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  FereshtehnejadS. M.ZeighamiY.DagherA.PostumaR. B. (2017). Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain140, 1959–1976. doi: 10.1093/brain/awx118

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  FernandezC. O.HoyerW.ZweckstetterM.Jares-ErijmanE. A.SubramaniamV.GriesingerC.et al. (2004). NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J.23, 2039–2046. doi: 10.1038/sj.emboj.7600211

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  FernandezE.Garcia-MorenoJ. M.Martin De PablosA.ChaconJ. (2013). May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum alpha-synuclein serve for diagnosis of sporadic Parkinson's disease?Antioxid. Redox Signal.19, 912–918. doi: 10.1089/ars.2013.5250

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  FieldsC. R.Bengoa-VergnioryN.Wade-MartinsR. (2019). Targeting alpha-Synuclein as a therapy for Parkinson's Disease. Front. Mol. Neurosci.12:299. doi: 10.3389/fnmol.2019.00299

  • CrossRef
  • Google Scholar

• 131

  FitzgeraldK.BergeronM.WillitsC.BowersS.AubeleD. L.GoldbachE.et al. (2013). Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei. Toxicol. Appl. Pharmacol.269, 1–7. doi: 10.1016/j.taap.2013.02.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  FlockG.BaggioL. L.LonguetC.DruckerD. J. (2007). Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes56, 3006–3013. doi: 10.2337/db07-0697

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  FloorE.WetzelM. G. (1998). Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem.70, 268–275. doi: 10.1046/j.1471-4159.1998.70010268.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  FormanH. J.DaviesK. J.UrsiniF. (2014). How do nutritional antioxidants really work: nucleophilic tone and Para-hormesis versus free radical scavenging in vivo. Free Radic. Biol. Med.66, 24–35. doi: 10.1016/j.freeradbiomed.2013.05.045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  FormanH. J.ZhangH. (2021). Author correction: targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat. Rev. Drug Discov.20:652. doi: 10.1038/s41573-021-00267-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  FormisanoL.GuidaN.LaudatiG.MascoloL.Di RenzoG.CanzonieroL. M. (2015). MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter. J. Pharmacol. Exp. Ther.352, 236–243. doi: 10.1124/jpet.114.219345

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  ForsterA.HillC. P. (2003). Proteasome degradation: enter the substrate. Trends Cell Biol.13, 550–553. doi: 10.1016/j.tcb.2003.09.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  FouldsP.MannD. M.AllsopD. (2012). Phosphorylated alpha-synuclein as a potential biomarker for Parkinson's disease and related disorders. Expert. Rev. Mol. Diagn.12, 115–117. doi: 10.1586/erm.12.5

  • CrossRef
  • Google Scholar

• 139

  FouldsP. G.DiggleP.MitchellJ. D.ParkerA.HasegawaM.Masuda-SuzukakeM.et al. (2013). A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci. Rep.3:2540. doi: 10.1038/srep02540

  • CrossRef
  • Google Scholar

• 140

  FouldsP. G.MitchellJ. D.ParkerA.TurnerR.GreenG.DiggleP.et al. (2011). Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J.25, 4127–4137. doi: 10.1096/fj.10-179192

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  FujiwaraH.HasegawaM.DohmaeN.KawashimaA.MasliahE.GoldbergM. S.et al. (2002). Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol.4, 160–164. doi: 10.1038/ncb748

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  FukudaI.ItoA.HiraiG.NishimuraS.KawasakiH.SaitohH.et al. (2009). Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol.16, 133–140. doi: 10.1016/j.chembiol.2009.01.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143

  FumimuraY.IkemuraM.SaitoY.SengokuR.KanemaruK.SawabeM.et al. (2007). Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J. Neuropathol. Exp. Neurol.66, 354–362. doi: 10.1097/nen.0b013e3180517454

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144

  GangulyU.SinghS.PalS.PrasadS.AgrawalB. K.SainiR. V.et al. (2021). Alpha-synuclein as a biomarker of Parkinson's disease: good, but not good enough. Front. Aging Neurosci.13:702639. doi: 10.3389/fnagi.2021.702639

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  GardianG.YangL.ClerenC.CalingasanN. Y.KlivenyiP.BealM. F. (2004). Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. NeuroMolecular Med.5, 235–241. doi: 10.1385/NMM:5:3:235

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  GelpiE.Navarro-OtanoJ.TolosaE.GaigC.ComptaY.ReyM. J.et al. (2014). Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov. Disord.29, 1010–1018. doi: 10.1002/mds.25776

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  GeorgeJ. M. (2002). The Synucleins. Genome Biol.3:Reviews3002. doi: 10.1186/gb-2001-3-1-reviews3002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  GeorgeS.AbrahamseH. (2020). Redox potential of antioxidants in cancer progression and prevention. Antioxidants9:1156. doi: 10.3390/antiox9111156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  GerlachM.DoubleK. L.Ben-ShacharD.ZeccaL.YoudimM. B.RiedererP. (2003). Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox. Res.5, 35–44. doi: 10.1007/BF03033371

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  GetachewB.CsokaA. B.BhattiA.CopelandR. L.TizabiY. (2020). Butyrate protects against salsolinol-induced toxicity in SH-SY5Y cells: implication for Parkinson's disease. Neurotox. Res.38, 596–602. doi: 10.1007/s12640-020-00238-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  GhanemS. S.MajbourN. K.VaikathN. N.ArdahM. T.ErskineD.JensenN. M.et al. (2022). Alpha-synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl. Acad. Sci. U. S. A.119:e2109617119. doi: 10.1073/pnas.2109617119

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  GhiglieriV.CalabreseV.CalabresiP. (2018). Alpha-Synuclein: from early synaptic dysfunction to Neurodegeneration. Front. Neurol.9:295. doi: 10.3389/fneur.2018.00295

  • CrossRef
  • Google Scholar

• 153

  GiassonB. I.DudaJ. E.FormanM. S.LeeV. M.TrojanowskiJ. Q. (2001). Prominent perikaryal expression of alpha-and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. Exp. Neurol.172, 354–362. doi: 10.1006/exnr.2001.7805

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  GiassonB. I.DudaJ. E.MurrayI. V.ChenQ.SouzaJ. M.HurtigH. I.et al. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science290, 985–989. doi: 10.1126/science.290.5493.985

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  GiassonB. I.FormanM. S.HiguchiM.GolbeL. I.GravesC. L.KotzbauerP. T.et al. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science300, 636–640. doi: 10.1126/science.1082324

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  GibbW. R. (1986). Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol. Appl. Neurobiol.12, 223–234. doi: 10.1111/j.1365-2990.1986.tb00136.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  GiladE.WongH. R.ZingarelliB.ViragL.O'connorM.SalzmanA. L.et al. (1998). Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J.12, 685–693. doi: 10.1096/fasebj.12.9.685

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  GilleG.HungS. T.ReichmannH.RauschW. D. (2004). Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. N. Y. Acad. Sci.1018, 533–540. doi: 10.1196/annals.1296.066

  • CrossRef
  • Google Scholar

• 159

  GioVanniniM. G.CerbaiF.BellucciA.MelaniC.GrossiC.BartolozziC.et al. (2008). Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease. Neuroscience153, 618–633. doi: 10.1016/j.neuroscience.2008.02.061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  GiovanniniM. G.ScaliC.ProsperiC.BellucciA.VannucchiM. G.RosiS.et al. (2002). Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis.11, 257–274. doi: 10.1006/nbdi.2002.0538

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  GodenaV. K.Brookes-HockingN.MollerA.ShawG.OswaldM.SanchoR. M.et al. (2014). Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat. Commun.5:5245. doi: 10.1038/ncomms6245

  • CrossRef
  • Google Scholar

• 162

  GoedertM.JakesR.SpillantiniM. G. (2017). The synucleinopathies: twenty years on. J. Parkinsons Dis.7, S51–S69. doi: 10.3233/JPD-179005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  Gomez-TortosaE.NewellK.IrizarryM. C.SandersJ. L.HymanB. T. (2000). Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol.99, 352–357. doi: 10.1007/s004010051135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  GonfloniS.MaianiE.Di BartolomeoC.DiederichM.CesareniG. (2012). Oxidative stress, DNA damage, and c-Abl signaling: at the crossroad in neurodegenerative diseases?Int. J. Cell. Biol.2012:683097. doi: 10.1155/2012/683097

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  GongB.PanY.VempatiP.ZhaoW.KnableL.HoL.et al. (2013). Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging34, 1581–1588. doi: 10.1016/j.neurobiolaging.2012.12.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  GongC. X.LiuF.IqbalK. (2012). O-GlcNAc cycling modulates neurodegeneration. Proc. Natl. Acad. Sci. U. S. A.109, 17319–17320. doi: 10.1073/pnas.1215395109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  GorbatyukO. S.LiS.SullivanL. F.ChenW.KondrikovaG.ManfredssonF. P.et al. (2008). The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A.105, 763–768. doi: 10.1073/pnas.0711053105

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  GorostidiA.BergarecheA.Ruiz-MartinezJ.Marti-MassoJ. F.CruzM.VargheseS.et al. (2012). Alphalpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One7:e52312. doi: 10.1371/journal.pone.0052312

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  GraceA. A.BunneyB. S. (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—3. Evidence for electrotonic coupling. Neuroscience10, 333–348. doi: 10.1016/0306-4522(83)90137-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  GrahamD. L.GrayA. J.JoyceJ. A.YuD.OmooreJ.CarlsonG. A.et al. (2014). Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology79, 307–313. doi: 10.1016/j.neuropharm.2013.11.025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  GreenamyreJ. T.HastingsT. G. (2004). Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science304, 1120–1122. doi: 10.1126/science.1098966

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  GruschusJ. M.YapT. L.PistolesiS.MaltsevA. S.LeeJ. C. (2013). NMR structure of calmodulin complexed to an N-terminally acetylated alpha-synuclein peptide. Biochemistry52, 3436–3445. doi: 10.1021/bi400199p

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  GuevenN.RavishankarP.EriR.RybalkaE. (2021). Idebenone: when an antioxidant is not an antioxidant. Redox Biol.38:101812. doi: 10.1016/j.redox.2020.101812

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  GuoY. J.DongS. Y.CuiX. X.FengY.LiuT.YinM.et al. (2016). Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of alpha-synuclein via SIRT1-deacetylated LC3. Mol. Nutr. Food Res.60, 2161–2175. doi: 10.1002/mnfr.201600111

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175

  GuzmanE.TaylorG.CharlestonB.EllisS. A. (2010). Induction of a cross-reactive CD8(+) T cell response following foot-and-mouth disease virus vaccination. J. Virol.84, 12375–12384. doi: 10.1128/JVI.01545-10

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  Hamm-AlvarezS. F.OkamotoC. T.JangaS. R.FeigenbaumD.EdmanM. C.FreireD.et al. (2019). Oligomeric alpha-synuclein is increased in basal tears of Parkinson's patients. Biomark. Med13, 941–952. doi: 10.2217/bmm-2019-0167

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  HanS.DuZ.LiuK.GongS. (2020). Nicotinamide riboside protects noise-induced hearing loss by recovering the hair cell ribbon synapses. Neurosci. Lett.725:134910. doi: 10.1016/j.neulet.2020.134910

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  HarderZ.ZuninoR.McbrideH. (2004). Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr. Biol.14, 340–345. doi: 10.1016/j.cub.2004.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  HarlanB. A.KilloyK. M.PeharM.LiuL.AuwerxJ.VargasM. R. (2020). Evaluation of the NAD(+) biosynthetic pathway in ALS patients and effect of modulating NAD(+) levels in hSOD1-linked ALS mouse models. Exp. Neurol.327:113219. doi: 10.1016/j.expneurol.2020.113219

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  HarrisI. S.DenicolaG. M. (2020). The complex interplay between antioxidants and ROS in Cancer. Trends Cell Biol.30, 440–451. doi: 10.1016/j.tcb.2020.03.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  HarrisonI. F.CrumW. R.VernonA. C.DexterD. T. (2015). Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. Br. J. Pharmacol.172, 4200–4215. doi: 10.1111/bph.13208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  HarrisonI. F.SmithA. D.DexterD. T. (2018). Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. Neurosci. Lett.666, 48–57. doi: 10.1016/j.neulet.2017.12.037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  HasegawaM.FujiwaraH.NonakaT.WakabayashiK.TakahashiH.LeeV. M.et al. (2002). Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem.277, 49071–49076. doi: 10.1074/jbc.M208046200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  HastingsN. B.WangX.SongL.ButtsB. D.GrotzD.HargreavesR.et al. (2017). Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol. Neurodegener.12:39. doi: 10.1186/s13024-017-0181-0

  • CrossRef
  • Google Scholar

• 185

  HeP. K.GaoY. Y.LyuF. J.ChenJ. N.ZhangY. H.NieK.et al. (2021). Idebenone-activating Autophagic degradation of alpha-synuclein via inhibition of AKT-mTOR pathway in a SH-SY5Y-A53T model of Parkinson's disease: a network pharmacological approach. Evid. Based Complement. Alternat. Med.2021:8548380. doi: 10.1155/2021/8548380

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  HeX.RicebergJ.SoucyT.KoenigE.MinissaleJ.GalleryM.et al. (2017). Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat. Chem. Biol.13, 1164–1171. doi: 10.1038/nchembio.2463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  HeY.YuZ.ChenS. (2019). Alpha-synuclein nitration and its implications in Parkinson's disease. ACS Chem. Neurosci.10, 777–782. doi: 10.1021/acschemneuro.8b00288

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  HebronM. L.LonskayaI.MoussaC. E. (2013). Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum. Mol. Genet.22, 3315–3328. doi: 10.1093/hmg/ddt192

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  HellenbrandW.BoeingH.RobraB. P.SeidlerA.ViereggeP.NischanP.et al. (1996). Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology47, 644–650. doi: 10.1212/WNL.47.3.644

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  HenningC.GlombM. A. (2016). Pathways of the Maillard reaction under physiological conditions. Glycoconj. J.33, 499–512. doi: 10.1007/s10719-016-9694-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  HershkoA.CiechanoverA. (1998). The ubiquitin system. Annu. Rev. Biochem.67, 425–479. doi: 10.1146/annurev.biochem.67.1.425

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  HirataY.SasakiT.KankiH.ChoongC. J.NishiyamaK.KuboG.et al. (2018). New 5-aryl-substituted 2-aminobenzamide-type HDAC inhibitors with a diketopiperazine group and their ameliorating effects on ischemia-induced neuronal cell death. Sci. Rep.8:1400. doi: 10.1038/s41598-018-19664-9

  • CrossRef
  • Google Scholar

• 193

  HIrohamaM.KumarA.FukudaI.MatsuokaS.IgarashiY.SaitohH.et al. (2013). Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem. Biol.8, 2635–2642. doi: 10.1021/cb400630z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  HodaraR.NorrisE. H.GiassonB. I.Mishizen-EberzA. J.LynchD. R.LeeV. M.et al. (2004). Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem.279, 47746–47753. doi: 10.1074/jbc.M408906200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  HodgeJ. E. (1955). The Amadori rearrangement. Adv. Carbohydr. Chem.10, 169–205. doi: 10.1016/s0096-5332(08)60392-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  HolmayM. J.TerpstraM.ColesL. D.MishraU.AhlskogM.OzG.et al. (2013). N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin. Neuropharmacol.36, 103–106. doi: 10.1097/WNF.0b013e31829ae713

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  HolstJ. J. (2007). The physiology of glucagon-like peptide 1. Physiol. Rev.87, 1409–1439. doi: 10.1152/physrev.00034.2006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  HongZ.ShiM.ChungK. A.QuinnJ. F.PeskindE. R.GalaskoD.et al. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain133, 713–726. doi: 10.1093/brain/awq008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  HornykiewiczO. (2001). Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease. J. Chem. Neuroanat.22, 3–12. doi: 10.1016/S0891-0618(01)00100-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200

  HorvathT. L.DianoS.LeranthC.Garcia-SeguraL. M.CowleyM. A.ShanabroughM.et al. (2003). Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology144, 2757–2760. doi: 10.1210/en.2003-0163

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201

  HoyerW.ChernyD.SubramaniamV.JovinT. M. (2004). Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry43, 16233–16242. doi: 10.1021/bi048453u

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202

  HsuS. W.HsuP. C.ChangW. S.YuC. C.WangY. C.YangJ. S.et al. (2020). Protective effects of valproic acid on 6-hydroxydopamine-induced neuroinjury. Environ. Toxicol.35, 840–848. doi: 10.1002/tox.22920

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  HughesK. C.GaoX.KimI. Y.RimmE. B.WangM.WeisskopfM. G.et al. (2016). Intake of antioxidant vitamins and risk of Parkinson's disease. Mov. Disord.31, 1909–1914. doi: 10.1002/mds.26819

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204

  HulkaB. S. (1990). Principles of bladder cancer screening in an intervention trial. J. Occup. Med.32, 812–816. doi: 10.1097/00043764-199009000-00011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205

  IbrahimH. A. M.HusseinA. M.GabrM.El-SaeedR. A.AmmarO. A.MosaA. A. H.et al. (2022). Effect of melatonin on alpha synuclein and autophagy in dopaminergic neuronal differentiation of adipose mesenchymal stem cells. Res. Sq. doi: 10.21203/rs.3.rs-1746786/v

  • CrossRef
  • Google Scholar

• 206

  ImamS. Z.ZhouQ.YamamotoA.ValenteA. J.AliS. F.BainsM.et al. (2011). Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J. Neurosci.31, 157–163. doi: 10.1523/JNEUROSCI.1833-10.2011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207

  InfanteR.ScaglioneC.IncensiA.RizzoG.LiguoriR.DonadioV. (2020). A longitudinal skin biopsy study of phosphorylated alpha-synuclein in a patient with Parkinson disease and orthostatic hypotension. J. Neuropathol. Exp. Neurol.79, 813–816. doi: 10.1093/jnen/nlaa048

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  InglisK. J.ChereauD.BrighamE. F.ChiouS. S.SchobelS.FrigonN. L.et al. (2009). Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem.284, 2598–2602. doi: 10.1074/jbc.C800206200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  IntagliataS.ModicaM. N.SantagatiL. M.MontenegroL. (2019). Strategies to improve resveratrol systemic and topical bioavailability: an update. Antioxidants8:244. doi: 10.3390/antiox8080244

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  IravanpourF.DargahiL.RezaeiM.HaghaniM.HeidariR.ValianN.et al. (2021). Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease. CNS Neurosci. Ther.27, 308–319. doi: 10.1111/cns.13609

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  JennerP.OlanowC. W. (2006). The pathogenesis of cell death in Parkinson's disease. Neurology66, S24–S36. doi: 10.1212/WNL.66.10_suppl_4.S24

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  JensenP. H.HagerH.NielsenM. S.HojrupP.GliemannJ.JakesR. (1999). Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem.274, 25481–25489. doi: 10.1074/jbc.274.36.25481

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 213

  JeongS. H.ChungS. J.YooH. S.HongN.JungJ. H.BaikK.et al. (2021). Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease. Brain144, 1127–1137. doi: 10.1093/brain/awab015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214

  JiaL.WangY.WeiW.ZhaoW.LuF.LiuF. (2019). Vitamin B12 inhibits alpha-synuclein fibrillogenesis and protects against amyloid-induced cytotoxicity. Food Funct.10, 2861–2870. doi: 10.1039/C8FO02471E

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215

  JianW.WeiX.ChenL.WangZ.SunY.ZhuS.et al. (2017). Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury. Neurosci. Lett.658, 114–120. doi: 10.1016/j.neulet.2017.08.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  JinJ. W.FanX.Del Cid-PelliteroE.LiuX. X.ZhouL.DaiC.et al. (2021). Development of an alpha-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models. Commun. Biol.4:232. doi: 10.1038/s42003-021-01746-6

  • CrossRef
  • Google Scholar

• 217

  JohnstonT. H.HuotP.DamudeS.FoxS. H.JonesS. W.RuscheJ. R.et al. (2013). RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism Relat. Disord.19, 260–264. doi: 10.1016/j.parkreldis.2012.07.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218

  JomovaK.ValkoM. (2011). Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr. Pharm. Des.17, 3460–3473. doi: 10.2174/138161211798072463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219

  JonesC. L.NjomenE.SjogrenB.DexheimerT. S.TepeJ. J. (2017). Small molecule enhancement of 20S proteasome activity targets intrinsically disordered proteins. ACS Chem. Biol.12, 2240–2247. doi: 10.1021/acschembio.7b00489

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220

  JunnE.MouradianM. M. (2002). Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett.320, 146–150. doi: 10.1016/S0304-3940(02)00016-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221

  KabelA. M.OmarM. S.AlhadhramiA.AlharthiS. S.AlrobaianM. M. (2018). Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: role of toll-like receptor 4, TGF-beta1, NF-kappaB and glucagon-like peptide 1. Physiol. Behav.188, 108–118. doi: 10.1016/j.physbeh.2018.01.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222

  KahleP. J.NeumannM.OzmenL.HaassC. (2000). Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. N. Y. Acad. Sci.920, 33–41. doi: 10.1111/j.1749-6632.2000.tb06902.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  KangL.MoriartyG. M.WoodsL. A.AshcroftA. E.RadfordS. E.BaumJ. (2012). N-terminal acetylation of alpha-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci.21, 911–917. doi: 10.1002/pro.2088

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224

  KarachaliasN.Babaei-JadidiR.RabbaniN.ThornalleyP. J. (2010). Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia53, 1506–1516. doi: 10.1007/s00125-010-1722-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225

  KarampetsouM.ArdahM. T.SemitekolouM.PolissidisA.SamiotakiM.KalomoiriM.et al. (2017). Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Sci. Rep.7:16533. doi: 10.1038/s41598-017-15813-8

  • CrossRef
  • Google Scholar

• 226

  KargboR. B. (2020). PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: Alzheimer's and Parkinson's diseases. ACS Med. Chem. Lett.11, 1086–1087. doi: 10.1021/acsmedchemlett.0c00192

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227

  KaruppagounderS. S.BrahmachariS.LeeY.DawsonV. L.DawsonT. M.KoH. S. (2014). The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci. Rep.4:4874. doi: 10.1038/srep04874

  • CrossRef
  • Google Scholar

• 228

  KaruppagounderS. S.WangH.KellyT.RushR.NguyenR.BisenS.et al. (2023). The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci. Transl. Med.15:eabp9352.

  • Google Scholar

• 229

  KasaiT.TokudaT.YamaguchiN.WatanabeY.KametaniF.NakagawaM.et al. (2008). Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci. Lett.436, 52–56. doi: 10.1016/j.neulet.2008.02.057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230

  KatilaN.BhurtelS.ShadfarS.SrivastavS.NeupaneS.OjhaU.et al. (2017). Metformin lowers alpha-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease. Neuropharmacology125, 396–407. doi: 10.1016/j.neuropharm.2017.08.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231

  KawaguchiY.KovacsJ. J.MclaurinA.VanceJ. M.ItoA.YaoT. P. (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cells115, 727–738. doi: 10.1016/S0092-8674(03)00939-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232

  KazantsevA. G.KolchinskyA. M. (2008). Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol.65, 1577–1581. doi: 10.1001/archneur.65.12.1577

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233

  KeeneyP. M.XieJ.CapaldiR. A.BennettJ. P.Jr. (2006). Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci.26, 5256–5264. doi: 10.1523/JNEUROSCI.0984-06.2006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234

  KhanZ.AliS. A. (2018). Oxidative stress-related biomarkers in Parkinson's disease: a systematic review and meta-analysis. Iran. J. Neurol.17, 137–144. PMID:

  • Pubmed Abstract
  • Google Scholar

• 235

  KiddS. K.SchneiderJ. S. (2010). Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res.1354, 172–178. doi: 10.1016/j.brainres.2010.07.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236

  KiddS. K.SchneiderJ. S. (2011). Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience194, 189–194. doi: 10.1016/j.neuroscience.2011.08.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237

  KieburtzK.McdermottM.ComoP.GrowdonJ.BradyJ.CarterJ.et al. (1994). The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson study group. Neurology44, 1756–1759. doi: 10.1212/WNL.44.9.1756

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238

  KimD.NguyenM. D.DobbinM. M.FischerA.SananbenesiF.RodgersJ. T.et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J.26, 3169–3179. doi: 10.1038/sj.emboj.7601758

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 239

  KimD. S.ChoiH. I.WangY.LuoY.HofferB. J.GreigN. H. (2017). A new treatment strategy for Parkinson's disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant.26, 1560–1571. doi: 10.1177/0963689717721234

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240

  KimT.SongS.ParkY.KangS.SeoH. (2019). HDAC inhibition by valproic acid induces neuroprotection and improvement of PD-like behaviors in LRRK2 R1441G transgenic mice. Exp. Neurobiol.28, 504–515. doi: 10.5607/en.2019.28.4.504

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 241

  KoH. S.LeeY.ShinJ. H.KaruppagounderS. S.GadadB. S.KoleskeA. J.et al. (2010). Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl. Acad. Sci. U. S. A.107, 16691–16696. doi: 10.1073/pnas.1006083107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242

  KoehlerN. K.StranskyE.MeyerM.GaertnerS.ShingM.SchnaidtM.et al. (2015). Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One10:e0123444. doi: 10.1371/journal.pone.0123444

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243

  KongY.ZhouH.FengH.ZhuangJ.WenT.ZhangC.et al. (2020). Elucidating the relationship between diabetes mellitus and Parkinson's disease using (18) F-FP-(+)-DTBZ, a positron-emission tomography probe for vesicular monoamine transporter 2. Front. Neurosci.14:682.

  • Google Scholar

• 244

  KonigA.Vicente MirandaH.OuteiroT. F. (2018). Alpha-synuclein glycation and the action of anti-diabetic agents in Parkinson's disease. J. Parkinsons Dis.8, 33–43. doi: 10.3233/JPD-171285

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245

  KopytekM.ZabczykM.MazurP.UndasA.NatorskaJ. (2020). Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. Cardiovasc. Diabetol.19:92. doi: 10.3389/fnins.2020.00682

  • CrossRef
  • Google Scholar

• 246

  KorsS.GeijtenbeekK.ReitsE.Schipper-KromS. (2019). Regulation of proteasome activity by (Post-)transcriptional mechanisms. Front. Mol. Biosci.6:48. doi: 10.3389/fmolb.2019.00048

  • CrossRef
  • Google Scholar

• 247

  KostenJ.BinolfiA.StuiverM.VerziniS.TheilletF. X.BekeiB.et al. (2014). Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. ACS Chem. Neurosci.5, 1203–1208. doi: 10.1021/cn5002254

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248

  KrumovaP.MeulmeesterE.GarridoM.TirardM.HsiaoH. H.BossisG.et al. (2011). Sumoylation inhibits alpha-synuclein aggregation and toxicity. J. Cell Biol.194, 49–60. doi: 10.1083/jcb.201010117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249

  KulkarniA. S.BurnsM. R.BrundinP.WessonD. W. (2022). Linking alpha-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease. Brain Commun.4:fcac165. doi: 10.1093/braincomms/fcac165

  • CrossRef
  • Google Scholar

• 250

  KumariP.GhoshD.VanasA.FleischmannY.WiegandT.JeschkeG.et al. (2021). Structural insights into alpha-synuclein monomer-fibril interactions. Proc. Natl. Acad. Sci. U. S. A.118:e2012171118. doi: 10.1073/pnas.2012171118

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 251

  KunzD.BesF. (1999). Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov. Disord.14, 507–511. doi: 10.1002/1531-8257(199905)14:3<507::AID-MDS1021>3.0.CO;2-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 252

  KunzD.MahlbergR.MullerC.TilmannA.BesF. (2004). Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J. Clin. Endocrinol. Metab.89, 128–134. doi: 10.1210/jc.2002-021057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 253

  LandeckN.HallH.ArdahM. T.MajbourN. K.El-AgnafO. M.HallidayG.et al. (2016). A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Mol. Neurodegener.11:61. doi: 10.1186/s13024-016-0125-0

  • CrossRef
  • Google Scholar

• 254

  LashuelH. A. (2021). Rethinking protein aggregation and drug discovery in neurodegenerative diseases: why we need to embrace complexity?Curr. Opin. Chem. Biol.64, 67–75. doi: 10.1016/j.cbpa.2021.05.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 255

  LavedanC. (1998). The synuclein family. Genome Res.8, 871–880. doi: 10.1101/gr.8.9.871

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 256

  LeeJ. T.WheelerT. C.LiL.ChinL. S. (2008). Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet.17, 906–917. doi: 10.1093/hmg/ddm363

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 257

  LeiteK.GargP.SpitznerF. P.Guerin DarvasS.BahrM.PriesemannV.et al. (2022). Alpha-synuclein impacts on intrinsic neuronal network activity through reduced levels of cyclic AMP and diminished numbers of active presynaptic terminals. Front. Mol. Neurosci.15:868790. doi: 10.3389/fnmol.2022.868790

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 258

  LemosM.StefanovaN. (2020). Histone deacetylase 6 and the disease mechanisms of alpha-synucleinopathies. Front. Synaptic. Neurosci.12:586453. doi: 10.3389/fnsyn.2020.586453

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 259

  LevineP. M.De LeonC. A.GalesicA.BalanaA.MarottaN. P.LewisY. E.et al. (2017). O-GlcNAc modification inhibits the calpain-mediated cleavage of alpha-synuclein. Bioorg. Med. Chem.25, 4977–4982. doi: 10.1016/j.bmc.2017.04.038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 260

  LevineP. M.GalesicA.BalanaA. T.Mahul-MellierA. L.NavarroM. X.De LeonC. A.et al. (2019). Alpha-synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A.116, 1511–1519. doi: 10.1073/pnas.1808845116

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 261

  LewisY. E.GalesicA.LevineP. M.De LeonC. A.LamiriN.BrennanC. K.et al. (2017). O-GlcNAcylation of alpha-synuclein at serine 87 reduces aggregation without affecting membrane binding. ACS Chem. Biol.12, 1020–1027. doi: 10.1021/acschembio.7b00113

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 262

  LiB.WangX.RasheedN.HuY.BoastS.IshiiT.et al. (2004). Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev.18, 1824–1837. doi: 10.1101/gad.1223504

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 263

  LiS.PelletierG. (1995). Effects of pinealectomy and melatonin on gonadotropin-releasing hormone (GnRH) gene expression in the male rat brain. Endocrine3, 533–536. doi: 10.1007/BF02738829

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 264

  LiX. Y.LiW.LiX.LiX. R.SunL.YangW.et al. (2021). Alterations of erythrocytic phosphorylated alpha-synuclein in different subtypes and stages of Parkinson's disease. Front. Aging Neurosci.13:623977. doi: 10.3389/fnagi.2021.623977

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 265

  LiX. Y.YangW.LiX.LiX. R.LiW.SongQ.et al. (2020). Phosphorylated alpha-synuclein in red blood cells as a potential diagnostic biomarker for multiple system atrophy: a pilot study. Parkinsons Dis.2020:8740419. doi: 10.1155/2020/8740419

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 266

  LinT. K.LinK. J.LinH. Y.LinK. L.LanM. Y.WangP. W.et al. (2021). Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing alpha-Synuclein and Oxidative Stress. Front. Mol. Neurosci.14:697440. doi: 10.3389/fnmol.2021.697440

  • CrossRef
  • Google Scholar

• 267

  LinC. H.LiuH. C.YangS. Y.YangK. C.WuC. C.ChiuM. J. (2019). Plasma pS129-alpha-synuclein is a surrogate biofluid marker of motor severity and progression in Parkinson's disease. J. Clin. Med.8:1601. doi: 10.3390/jcm8101601

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 268

  LiuF.IqbalK.Grundke-IqbalI.HartG. W.GongC. X. (2004a). O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A.101, 10804–10809. doi: 10.1073/pnas.0400348101

  • CrossRef
  • Google Scholar

• 269

  LiuS.FaM.NinanI.TrincheseF.DauerW.ArancioO. (2007). Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. Eur. J. Neurosci.25, 3583–3596. doi: 10.1111/j.1460-9568.2007.05569.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 270

  LiuS.NinanI.AntonovaI.BattagliaF.TrincheseF.NarasannaA.et al. (2004b). Alpha-synuclein produces a long-lasting increase in neurotransmitter release. EMBO J.23, 4506–4516. doi: 10.1038/sj.emboj.7600451

  • CrossRef
  • Google Scholar

• 271

  LiuW.JalewaJ.SharmaM.LiG.LiL.HolscherC. (2015). Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience303, 42–50. doi: 10.1016/j.neuroscience.2015.06.054

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 272

  LokireddyS.KukushkinN. V.GoldbergA. L. (2015). cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc. Natl. Acad. Sci. U. S. A.112, E7176–E7185. doi: 10.1073/pnas.1522332112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 273

  LonghenaF.FaustiniG.MissaleC.PizziM.SpanoP.BellucciA. (2017). The contribution of alpha-Synuclein spreading to Parkinson's Disease Synaptopathy. Neural Plast.2017:5012129. doi: 10.1155/2017/5012129

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 274

  LonghenaF.FaustiniG.SpillantiniM. G.BellucciA. (2019). Living in promiscuity: the multiple Partners of alpha-synuclein at the synapse in physiology and pathology. Int. J. Mol. Sci.20:141. doi: 10.3390/ijms20010141

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 275

  Lopez-BurilloS.TanD. X.MayoJ. C.SainzR. M.ManchesterL. C.ReiterR. J. (2003). Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J. Pineal Res.34, 269–277. doi: 10.1034/j.1600-079X.2003.00041.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 276

  LopezL. C.EscamesG.TapiasV.UtrillaP.LeonJ.Acuna-CastroviejoD. (2006). Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: its relation with mitochondrial dysfunction and prevention by melatonin. Int. J. Biochem. Cell Biol.38, 267–278. doi: 10.1016/j.biocel.2005.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 277

  LudtmannM. H.AngelovaP. R.NinkinaN. N.GandhiS.BuchmanV. L.AbramovA. Y. (2016). Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J. Neurosci.36, 10510–10521. doi: 10.1523/JNEUROSCI.1659-16.2016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 278

  LundbladM.DecressacM.MattssonB.BjorklundA. (2012). Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U. S. A.109, 3213–3219. doi: 10.1073/pnas.1200575109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 279

  MaQ. L.ChanP.YoshiiM.UedaK. (2003). Alpha-synuclein aggregation and neurodegenerative diseases. J. Alzheimers Dis.5, 139–148. doi: 10.3233/JAD-2003-5208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 280

  MaassF.RikkerS.DambeckV.WarthC.TatenhorstL.CsotiI.et al. (2020). Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease. Sci. Rep.10:8507. doi: 10.1038/s41598-020-65503-1

  • CrossRef
  • Google Scholar

• 281

  MagalhaesP.LashuelH. A. (2022). Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. NPJ Parkinsons Dis.8:93. doi: 10.1038/s41531-022-00357-0

  • CrossRef
  • Google Scholar

• 282

  MagistrettiP. J.PellerinL. (1996). Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann. N. Y. Acad. Sci.777, 380–387.

  • Google Scholar

• 283

  Mahul-MellierA. L.FauvetB.GysbersA.DikiyI.OueslatiA.GeorgeonS.et al. (2014). C-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum. Mol. Genet.23, 2858–2879. doi: 10.1093/hmg/ddt674

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 284

  MajbourN. K.VaikathN. N.EusebiP.ChiasseriniD.ArdahM.VargheseS.et al. (2016a). Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. Mov. Disord.31, 1535–1542. doi: 10.1002/mds.26754

  • CrossRef
  • Google Scholar

• 285

  MajbourN. K.VaikathN. N.Van DijkK. D.ArdahM. T.VargheseS.VesteragerL. B.et al. (2016b). Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol. Neurodegener.11:7. doi: 10.1186/s13024-016-0072-9

  • CrossRef
  • Google Scholar

• 286

  MalekN.SwallowD.GrossetK. A.AnichtchikO.SpillantiniM.GrossetD. G. (2014). Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol. Scand.130, 59–72. doi: 10.1111/ane.12247

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 287

  MandhaneS.SoniD.JaniK.SenguptaP.PatelA.BambalR.et al. (2019). K0706, a potent orally bioavailable brain-penetrating selective inhibitor of cABL protein tyrosine kinase, exhibits neuroprotective activity in preclinical models of Parkinson’s disease [online] Available at: https://www.mdsabstracts.org/abstract/k0706-a-potent-orally-bioavailable-brain-penetrating-selective-inhibitor-of-cabl-protein-tyrosine-kinase-exhibits-neuroprotective-activity-in-preclinical-models-of-parkinsons-disease/ [Accessed May 3, 2023].

  • Google Scholar

• 288

  MannV. M.CooperJ. M.DanielS. E.SraiK.JennerP.MarsdenC. D.et al. (1994). Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol.36, 876–881. doi: 10.1002/ana.410360612

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 289

  ManzanzaN. O.SedlackovaL.KalariaR. N. (2021). Alpha-synuclein post-translational modifications: implications for pathogenesis of Lewy body disorders. Front. Aging Neurosci.13:690293. doi: 10.3389/fnagi.2021.690293

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 290

  MarottaN. P.LinY. H.LewisY. E.AmbrosoM. R.ZaroB. W.RothM. T.et al. (2015). O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson's disease. Nat. Chem.7, 913–920. doi: 10.1038/nchem.2361

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 291

  MarouiM. A.MaarifiG.McmanusF. P.LamoliatteF.ThibaultP.Chelbi-AlixM. K. (2018). Promyelocytic leukemia protein (PML) requirement for interferon-induced global cellular SUMOylation. Mol. Cell. Proteomics17, 1196–1208. doi: 10.1074/mcp.RA117.000447

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 292

  MasatoA.PlotegherN.TerrinF.SandreM.FaustiniG.ThorA.et al. (2023). DOPAL initiates alphaSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson's disease. NPJ Parkinsons Dis.9:42. doi: 10.1038/s41531-023-00485-1

  • CrossRef
  • Google Scholar

• 293

  MatsubaraT. (1991). Interleukin 6 activities and tumor necrosis factor-alpha levels in serum of patients with Kawasaki disease. Arerugi40, 147–154. PMID:

  • Pubmed Abstract
  • Google Scholar

• 294

  MatsuraT. (2019). Protective effect of tocotrienol on in vitro and in vivo models of Parkinson's disease. J. Nutr. Sci. Vitaminol. (Tokyo)65, S51–S53. doi: 10.3177/jnsv.65.S51

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 295

  MatunisM. J.CoutavasE.BlobelG. (1996). A novel ubiquitin-like modification modulates the partitioning of the ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol.135, 1457–1470. doi: 10.1083/jcb.135.6.1457

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 296

  MaxwellM. M.TomkinsonE. M.NoblesJ.WizemanJ. W.AmoreA. M.QuintiL.et al. (2011). The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet.20, 3986–3996. doi: 10.1093/hmg/ddr326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 297

  MayeuxR. (2004). Biomarkers: potential uses and limitations. NeuroRx1, 182–188. doi: 10.1602/neurorx.1.2.182

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 298

  MazzocchiM.GouldingS. R.WyattS. L.CollinsL. M.SullivanA. M.O'keeffeG. W. (2021). LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin-and alpha-synuclein-induced degeneration in cellular models of Parkinson's disease. Mol. Cell. Neurosci.115:103642. doi: 10.1016/j.mcn.2021.103642

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 299

  MbefoM. K.PaleologouK. E.BoucharabaA.OueslatiA.SchellH.FournierM.et al. (2010). Phosphorylation of synucleins by members of the polo-like kinase family. J. Biol. Chem.285, 2807–2822. doi: 10.1074/jbc.M109.081950

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 300

  MedeirosA. T.SollL. G.TessariI.BubaccoL.MorganJ. R. (2017). Alpha-synuclein dimers impair vesicle fission during clathrin-mediated synaptic vesicle recycling. Front. Cell. Neurosci.11:388. doi: 10.3389/fncel.2017.00388

  • CrossRef
  • Google Scholar

• 301

  MehdiS. J.Rosas-HernandezH.CuevasE.LantzS. M.BargerS. W.SarkarS.et al. (2016). Protein kinases and Parkinson's disease. Int. J. Mol. Sci.17:1585. doi: 10.3390/ijms17091585

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 302

  MehmelM.JovanovicN.SpitzU. (2020). Nicotinamide Riboside-the current state of research and therapeutic uses. Nutrients12:1616. doi: 10.3390/nu12061616

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 303

  MehringerJ.NavarroJ. A.TouraudD.SchneuwlyS.KunzW. (2022). Phosphorylated resveratrol as a protein aggregation suppressor in vitro and in vivo. RSC Chem. Biol.3, 250–260. doi: 10.1039/D1CB00220A

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 304

  MengesS.MinakakiG.SchaeferP. M.MeixnerH.ProtsI.Schlotzer-SchrehardtU.et al. (2017). Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress. Sci. Rep.7:42942. doi: 10.1038/srep42942

  • CrossRef
  • Google Scholar

• 305

  MenkeT.GilleG.ReberF.JanetzkyB.AndlerW.FunkR. H.et al. (2003). Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential. Biofactors18, 65–72. doi: 10.1002/biof.5520180208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 306

  MiyakeY.FukushimaW.TanakaK.SasakiS.KiyoharaC.TsuboiY.et al. (2011). Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. Eur. J. Neurol.18, 106–113. doi: 10.1111/j.1468-1331.2010.03088.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 307

  MolinaJ. A.De BustosF.OrtizS.Del SerT.SeijoM.Benito-LeonJ.et al. (2002). Serum levels of coenzyme Q in patients with Lewy body disease. J. Neural Transm. (Vienna)109, 1195–1201. doi: 10.1007/s00702-001-0761-5

  • CrossRef
  • Google Scholar

• 308

  MollenhauerB.BatrlaR.El-AgnafO.GalaskoD. R.LashuelH. A.MerchantK. M.et al. (2017). A user's guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations. Mov. Disord.32, 1117–1130. doi: 10.1002/mds.27090

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 309

  MollenhauerB.TrautmannE.TaylorP.ManningerP.Sixel-DoringF.EbentheuerJ.et al. (2013). Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett.532, 44–48. doi: 10.1016/j.neulet.2012.11.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 310

  MontenegroL.TurnaturiR.ParentiC.PasquinucciL. (2018). Idebenone: novel strategies to improve its systemic and local efficacy. Nanomaterials8:87. doi: 10.3390/nano8020087

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 311

  MontiD. A.ZabreckyG.KremensD.LiangT. W.WinteringN. A.CaiJ.et al. (2016). N-acetyl cysteine may support dopamine neurons in Parkinson's disease: preliminary clinical and cell line data. PLoS One11:e0157602. doi: 10.1371/journal.pone.0157602

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 312

  MooreD. J.WestA. B.DawsonV. L.DawsonT. M. (2005). Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci.28, 57–87. doi: 10.1146/annurev.neuro.28.061604.135718

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 313

  MorensD. M.GrandinettiA.WaslienC. I.ParkC. B.RossG. W.WhiteL. R. (1996). Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology46, 1270–1274. doi: 10.1212/WNL.46.5.1270

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 314

  MosleyR. L.BennerE. J.KadiuI.ThomasM.BoskaM. D.HasanK.et al. (2006). Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's Disease. Clin. Neurosci. Res.6, 261–281. doi: 10.1016/j.cnr.2006.09.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 315

  MullerS.HoegeC.PyrowolakisG.JentschS. (2001). SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol.2, 202–210. doi: 10.1038/35056591

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 316

  MunchG.LuthH. J.WongA.ArendtT.HirschE.RavidR.et al. (2000). Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?J. Chem. Neuroanat.20, 253–257. doi: 10.1016/S0891-0618(00)00096-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 317

  NakamuraT.YamashitaH.TakahashiT.NakamuraS. (2001). Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun.280, 1085–1092. doi: 10.1006/bbrc.2000.4253

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 318

  NassarN. N.Al-ShorbagyM. Y.ArabH. H.AbdallahD. M. (2015). Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology89, 308–317. doi: 10.1016/j.neuropharm.2014.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 319

  NauckM. A.MeierJ. J. (2018). Incretin hormones: their role in health and disease. Diabetes Obes. Metab.20, 5–21. doi: 10.1111/dom.13129

  • CrossRef
  • Google Scholar

• 320

  NaylorS. (2003). Biomarkers: current perspectives and future prospects. Expert. Rev. Mol. Diagn.3, 525–529. doi: 10.1586/14737159.3.5.525

  • CrossRef
  • Google Scholar

• 321

  NegroA.BrunatiA. M.Donella-DeanaA.MassiminoM. L.PinnaL. A. (2002). Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J.16, 210–212. doi: 10.1096/fj.01-0517fje

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 322

  OhrfeltA.ZetterbergH.AnderssonK.PerssonR.SecicD.BrinkmalmG.et al. (2011). Identification of novel alpha-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem. Res.36, 2029–2042. doi: 10.1007/s11064-011-0527-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 323

  OkochiM.WalterJ.KoyamaA.NakajoS.BabaM.IwatsuboT.et al. (2000). Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem.275, 390–397. doi: 10.1074/jbc.275.1.390

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 324

  OliveiraL. M. A.GasserT.EdwardsR.ZweckstetterM.MelkiR.StefanisL.et al. (2021). Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. NPJ Parkinsons Dis.7:65. doi: 10.1038/s41531-021-00203-9

  • CrossRef
  • Google Scholar

• 325

  OnoK.YamadaM. (2007). Vitamin a potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases. Neurobiol. Dis.25, 446–454. doi: 10.1016/j.nbd.2006.10.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 326

  OnoK.YoshiikeY.TakashimaA.HasegawaK.NaikiH.YamadaM. (2004). Vitamin a exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp. Neurol.189, 380–392. doi: 10.1016/j.expneurol.2004.05.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 327

  OrsucciD.MancusoM.IencoE. C.LogerfoA.SicilianoG. (2011). Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr. Med. Chem.18, 4053–4064. doi: 10.2174/092986711796957257

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 328

  OueslatiA.FournierM.LashuelH. A. (2010). Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res.183, 115–145. doi: 10.1016/S0079-6123(10)83007-9

  • CrossRef
  • Google Scholar

• 329

  OueslatiA.PaleologouK. E.SchneiderB. L.AebischerP.LashuelH. A. (2012). Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci.32, 1536–1544. doi: 10.1523/JNEUROSCI.3784-11.2012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 330

  OueslatiA.SchneiderB. L.AebischerP.LashuelH. A. (2013). Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. U. S. A.110, E3945–E3954. doi: 10.1073/pnas.1309991110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 331

  OuteiroT. F.KontopoulosE.AltmannS. M.KufarevaI.StrathearnK. E.AmoreA. M.et al. (2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science317, 516–519. doi: 10.1126/science.1143780

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 332

  PaganF.HebronM.ValadezE. H.Torres-YaghiY.HuangX.MillsR. R.et al. (2016). Nilotinib effects in Parkinson's disease and dementia with Lewy bodies. J. Parkinsons Dis.6, 503–517. doi: 10.3233/JPD-160867

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 333

  PaganF. L.HebronM. L.WilmarthB.Torres-YaghiY.LawlerA.MundelE. E.et al. (2020). Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson Disease: a phase 2 randomized clinical trial. JAMA Neurol.77, 309–317. doi: 10.1001/jamaneurol.2019.4200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 334

  PaganF. L.HebronM. L.WilmarthB.Torres-YaghiY.LawlerA.MundelE. E.et al. (2019). Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. Pharmacol. Res. Perspect.7:e00470. doi: 10.1002/prp2.470

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 335

  PaikS. R.ShinH. J.LeeJ. H.ChangC. S.KimJ. (1999). Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J.340, 821–828.

  • Google Scholar

• 336

  PaleologouK. E.OueslatiA.ShakkedG.RospigliosiC. C.KimH. Y.LambertoG. R.et al. (2010). Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci.30, 3184–3198. doi: 10.1523/JNEUROSCI.5922-09.2010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 337

  PalleriaC.LeoA.AndreozziF.CitraroR.IannoneM.SpigaR.et al. (2017). Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. Behav. Brain Res.321, 157–169. doi: 10.1016/j.bbr.2017.01.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 338

  ParekhP.SharmaN.SharmaM.GadepalliA.SayyedA. A.ChatterjeeS.et al. (2022). AMPK-dependent autophagy activation and alpha-synuclein clearance: a putative mechanism behind alpha-mangostin's neuroprotection in a rotenone-induced mouse model of Parkinson's disease. Metab. Brain Dis.37, 2853–2870. doi: 10.1007/s11011-022-01087-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 339

  ParkG.TanJ.GarciaG.KangY.SalvesenG.ZhangZ. (2016). Regulation of histone acetylation by autophagy in Parkinson disease. J. Biol. Chem.291, 3531–3540. doi: 10.1074/jbc.M115.675488

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 340

  Parkinson Study GroupBealM. F.OakesD.ShoulsonI.HenchcliffeC.GalpernW. R.et al. (2014). A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol.71, 543–552. doi: 10.1001/jamaneurol.2014.131

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 341

  ParnettiL.GaetaniL.EusebiP.PaciottiS.HanssonO.El-AgnafO.et al. (2019). CSF and blood biomarkers for Parkinson's disease. Lancet Neurol.18, 573–586. doi: 10.1016/S1474-4422(19)30024-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 342

  PaxinouE.ChenQ.WeisseM.GiassonB. I.NorrisE. H.RueterS. M.et al. (2001). Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci.21, 8053–8061. doi: 10.1523/JNEUROSCI.21-20-08053.2001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 343

  PearsonK. J.BaurJ. A.LewisK. N.PeshkinL.PriceN. L.LabinskyyN.et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab.8, 157–168. doi: 10.1016/j.cmet.2008.06.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 344

  PercarioS.Da Silva BarbosaA.VarelaE. L. P.GomesA. R. Q.FerreiraM. E. S.MoreiraD. N. A.et al. (2020). Oxidative stress in Parkinson's Disease: potential benefits of antioxidant supplementation. Oxidative Med. Cell. Longev.2020:2360872. doi: 10.1155/2020/2360872

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 345

  PermanneB.SandA.OussonS.NenyM.HantsonJ.SchubertR.et al. (2022). O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for Tau and alpha-synuclein proteinopathies. ACS Chem. Neurosci.13, 1296–1314. doi: 10.1021/acschemneuro.2c00057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 346

  PetriccaL.ChikiN.Hanna-El-DaherL.AeschbachL.BuraiR.StoopsE.et al. (2022). Comparative analysis of Total alpha-synuclein (alphaSYN) immunoassays reveals that they do not capture the diversity of modified alphaSYN proteoforms. J. Parkinsons Dis.12, 1449–1462. doi: 10.3233/JPD-223285

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 347

  PfeifferR. F. (2016). Non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord.22, S119–S122. doi: 10.1016/j.parkreldis.2015.09.004

  • CrossRef
  • Google Scholar

• 348

  PiccaA.GuerraF.CalvaniR.MariniF.BiancolilloA.LandiG.et al. (2020). Mitochondrial signatures in circulating extracellular vesicles of older adults with Parkinson's disease: results from the EXosomes in PArkiNson's disease (EXPAND) study. J. Clin. Med.9:504. doi: 10.3390/jcm9020504

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 349

  PingF.JiangN.LiY. (2020). Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. BMJ Open Diabetes Res. Care8:e001370. doi: 10.1136/bmjdrc-2020-001370

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 350

  PinhoB. R.ReisS. D.Guedes-DiasP.Leitao-RochaA.QuintasC.ValentaoP.et al. (2016). Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson's disease. Pharmacol. Res.103, 328–339. doi: 10.1016/j.phrs.2015.11.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 351

  PissadakiE. K.BolamJ. P. (2013). The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci.7:13. doi: 10.3389/fncom.2013.00013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 352

  PoucletH.LebouvierT.CoronE.RouaudT.FlamantM.ToulgoatF.et al. (2012). Analysis of colonic alpha-synuclein pathology in multiple system atrophy. Parkinsonism Relat. Disord.18, 893–895. doi: 10.1016/j.parkreldis.2012.04.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 353

  PrickaertsJ.HeckmanP. R. A.BloklandA. (2017). Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Expert Opin. Investig. Drugs26, 1033–1048. doi: 10.1080/13543784.2017.1364360

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 354

  ProninA. N.MorrisA. J.SurguchovA.BenovicJ. L. (2000). Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem.275, 26515–26522. doi: 10.1074/jbc.M003542200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 355

  QingH.WongW.McgeerE. G.McgeerP. L. (2009a). Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun.387, 149–152. doi: 10.1016/j.bbrc.2009.06.142

  • CrossRef
  • Google Scholar

• 356

  QingH.ZhangY.DengY.McgeerE. G.McgeerP. L. (2009b). Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun.390, 1229–1234. doi: 10.1016/j.bbrc.2009.10.126

  • CrossRef
  • Google Scholar

• 357

  QualmanS. J.HauptH. M.YangP.HamiltonS. R. (1984). Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology87, 848–856. doi: 10.1016/0016-5085(84)90079-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 358

  QuastelJ. H.WheatleyA. H. (1932). Oxidations by the brain. Biochem. J.26, 725–744. doi: 10.1042/bj0260725

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 359

  RampersaudN.HarkavyiA.GiordanoG.LeverR.WhittONJ.WHittonP. (2012). Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. Br. J. Pharmacol.167, 1467–1479. doi: 10.1111/j.1476-5381.2012.02100.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 360

  RaneP.ShieldsJ.HeffernanM.GuoY.AkbarianS.KingJ. A. (2012). The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology62, 2409–2412. doi: 10.1016/j.neuropharm.2012.01.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 361

  ReesJ. N.FlorangV. R.EckertL. L.DoornJ. A. (2009). Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol.22, 1256–1263. doi: 10.1021/tx9000557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 362

  ReimerL.VesteragerL. B.BetzerC.ZhengJ.NielsenL. D.KofoedR. H.et al. (2018). Inflammation kinase PKR phosphorylates alpha-synuclein and causes alpha-synuclein-dependent cell death. Neurobiol. Dis.115, 17–28. doi: 10.1016/j.nbd.2018.03.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 363

  ReiterR. J.ParedesS. D.KorkmazA.JouM. J.TanD. X. (2008). Melatonin combats molecular terrorism at the mitochondrial level. Interdiscip. Toxicol.1, 137–149. doi: 10.2478/v10102-010-0030-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 364

  ReiterR. J.SainzR. M.Lopez-BurilloS.MayoJ. C.ManchesterL. C.TanD. X. (2003). Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann. N. Y. Acad. Sci.993, 35–47. discussion 48-53. doi: 10.1111/j.1749-6632.2003.tb07509.x

  • CrossRef
  • Google Scholar

• 365

  ReiterR. J.TanD. X.AllegraM. (2002a). Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuro Endocrinol. Lett.23, 3–8.

  • Google Scholar

• 366

  ReiterR. J.TanD. X.BurkhardtS. (2002b). Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech. Ageing Dev.123, 1007–1019. doi: 10.1016/s0047-6374(01)00384-0

  • CrossRef
  • Google Scholar

• 367

  ReiterR. J.TanD. X.LeonJ.KilicU.KilicE. (2005). When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp. Biol. Med.230, 104–117. doi: 10.1177/153537020523000205

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 368

  ReyN. L.GeorgeS.BrundinP. (2016a). Review: spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein. Neuropathol. Appl. Neurobiol.42, 51–76. doi: 10.1111/nan.12299

  • CrossRef
  • Google Scholar

• 369

  ReyN. L.GeorgeS.SteinerJ. A.MadajZ.LukK. C.TrojanowskiJ. Q.et al. (2018). Spread of aggregates after olfactory bulb injection of alpha-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol.135, 65–83. doi: 10.1007/s00401-017-1792-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 370

  ReyN. L.SteinerJ. A.MaroofN.LukK. C.MadajZ.TrojanowskiJ. Q.et al. (2016b). Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J. Exp. Med.213, 1759–1778. doi: 10.1084/jem.20160368

  • CrossRef
  • Google Scholar

• 371

  Richter-LandsbergC.LeykJ. (2013). Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathol.126, 793–807. doi: 10.1007/s00401-013-1158-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 372

  RisiglioneP.ZinghirinoF.Di RosaM. C.MagriA.MessinaA. (2021). Alpha-Synuclein and mitochondrial dysfunction in Parkinson's disease: the emerging role of VDAC. Biomol. Ther.11:718. doi: 10.3390/biom11050718

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 373

  RodriguezC.MayoJ. C.SainzR. M.AntolinI.HerreraF.MartinV.et al. (2004). Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res.36, 1–9. doi: 10.1046/j.1600-079X.2003.00092.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 374

  RodriguezM. I.EscamesG.LopezL. C.LopezA.GarciaJ. A.OrtizF.et al. (2007). Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence-accelerated mice. J. Pineal Res.42, 272–279. doi: 10.1111/j.1600-079X.2006.00416.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 375

  RossC. A.PickartC. M. (2004). The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol.14, 703–711. doi: 10.1016/j.tcb.2004.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 376

  RottR.SzargelR.HaskinJ.ShaniV.ShainskayaA.ManovI.et al. (2008). Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem.283, 3316–3328. doi: 10.1074/jbc.M704809200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 377

  RottR.SzargelR.ShaniV.HamzaH.SavyonM.Abd ElghaniF.et al. (2017). SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation. Proc. Natl. Acad. Sci. U. S. A.114, 13176–13181. doi: 10.1073/pnas.1704351114

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 378

  RousseauxM. W.RevelliJ. P.Vazquez-VelezG. E.KimJ. Y.CraigenE.GonzalesK.et al. (2018). Depleting Trim28 in adult mice is well tolerated and reduces levels of alpha-synuclein and tau. elife7:e36768. doi: 10.7554/eLife.36768

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 379

  RyanB. J.Lourenco-VendaL. L.CrabtreeM. J.HaleA. B.ChannonK. M.Wade-MartinsR. (2014). Alpha-synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radic. Biol. Med.67, 58–68. doi: 10.1016/j.freeradbiomed.2013.10.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 380

  RyuY. K.GoJ.ParkH. Y.ChoiY. K.SeoY. J.ChoiJ. H.et al. (2020). Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. Neuropharmacology175:108173. doi: 10.1016/j.neuropharm.2020.108173

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 381

  SajjaR. K.PrasadS.TangS.KaisarM. A.CuculloL. (2017). Blood-brain barrier disruption in diabetic mice is linked to Nrf2 signaling deficits: role of ABCB10?Neurosci. Lett.653, 152–158. doi: 10.1016/j.neulet.2017.05.059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 382

  SakamotoK. M.KimK. B.KumagaiA.MercurioF.CrewsC. M.DeshaiesR. J. (2001). Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. U. S. A.98, 8554–8559. doi: 10.1073/pnas.141230798

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 383

  SandersO.RajagopalL. (2020). Phosphodiesterase inhibitors for Alzheimer's disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J. Alzheimers Dis. Rep.4, 185–215. doi: 10.3233/ADR-200191

  • CrossRef
  • Google Scholar

• 384

  SatoK.YamashitaT.KurataT.LukicV.FukuiY.HishikawaN.et al. (2014). Telmisartan reduces progressive oxidative stress and phosphorylated alpha-synuclein accumulation in stroke-resistant spontaneously hypertensive rats after transient middle cerebral artery occlusion. J. Stroke Cerebrovasc. Dis.23, 1554–1563. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.051

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 385

  SatohA.ImaiS. (2014). Systemic regulation of mammalian ageing and longevity by brain sirtuins. Nat. Commun.5:4211. doi: 10.1038/ncomms5211

  • CrossRef
  • Google Scholar

• 386

  SavyonM.EngelenderS. (2020). SUMOylation in alpha-Synuclein homeostasis and pathology. Front. Aging Neurosci.12:167. doi: 10.3389/fnagi.2020.00167

  • CrossRef
  • Google Scholar

• 387

  SayinV. I.IbrahimM. X.LarssonE.NilssonJ. A.LindahlP.BergoM. O. (2014). Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med.6:221ra15. doi: 10.1126/scitranslmed.3007653

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 388

  SchapiraA. H. (2008). Mitochondrial dysfunction in neurodegenerative diseases. Neurochem. Res.33, 2502–2509. doi: 10.1007/s11064-008-9855-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 389

  SchapiraA. H.TolosaE. (2010). Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol.6, 309–317. doi: 10.1038/nrneurol.2010.52

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 390

  ScheiderW. L.HersheyL. A.VenaJ. E.HolmlundT.MarshallJ. R.Freudenheim (1997). Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov. Disord.12, 190–196. doi: 10.1002/mds.870120209

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 391

  SchepiciG.BramantiP.MazzonE. (2020). Efficacy of sulforaphane in neurodegenerative diseases. Int. J. Mol. Sci.21:8637. doi: 10.3390/ijms21228637

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 392

  SchirinziT.MartellaG.ImbrianiP.Di LazzaroG.FrancoD.ColonaV. L.et al. (2019). Dietary vitamin E as a protective factor for Parkinson's disease: clinical and experimental evidence. Front. Neurol.10:148. doi: 10.3389/fneur.2019.00148

  • CrossRef
  • Google Scholar

• 393

  SchmidA. W.FauvetB.MoniatteM.LashuelH. A. (2013). Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteomics12, 3543–3558. doi: 10.1074/mcp.R113.032730

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 394

  SchneiderS. A.AlcalayR. N. (2017). Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov. Disord.32, 1504–1523. doi: 10.1002/mds.27193

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 395

  SchondorfD. C.IvanyukD.BadenP.Sanchez-MartinezA.De CiccoS.YuC.et al. (2018). The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and Fly models of Parkinson's disease. Cell Rep.23, 2976–2988. doi: 10.1016/j.celrep.2018.05.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 396

  SelnickH. G.HessJ. F.TangC.LiuK.SchachterJ. B.BallardJ. E.et al. (2019). Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for Tauopathies. J. Med. Chem.62, 10062–10097. doi: 10.1021/acs.jmedchem.9b01090

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 397

  ShabekN.Herman-BachinskyY.BuchsbaumS.LewinsonO.Haj-YahyaM.HejjaouiM.et al. (2012). The size of the proteasomal substrate determines whether its degradation will be mediated by mono-or polyubiquitylation. Mol. Cell48, 87–97. doi: 10.1016/j.molcel.2012.07.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 398

  ShamsaldeenY. A.MackenzieL. S.LioneL. A.BenhamC. D. (2016). Methylglyoxal, a metabolite increased in diabetes is associated with insulin resistance, vascular dysfunction and neuropathies. Curr. Drug Metab.17, 359–367. doi: 10.2174/1389200217666151222155216

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 399

  ShannonK. M.KeshavarzianA.MutluE.DodiyaH. B.DaianD.JaglinJ. A.et al. (2012). Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord.27, 709–715. doi: 10.1002/mds.23838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 400

  SharmaS.TaliyanR.RamagiriS. (2015a). Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice. J. Mol. Neurosci.56, 1–11. doi: 10.1007/s12031-014-0461-x

  • CrossRef
  • Google Scholar

• 401

  SharmaS. K.ChorellE.StenebergP.Vernersson-LindahlE.EdlundH.Wittung-StafshedeP. (2015b). Insulin-degrading enzyme prevents alpha-synuclein fibril formation in a nonproteolytical manner. Sci. Rep.5:12531. doi: 10.1038/srep12531

  • CrossRef
  • Google Scholar

• 402

  SharmaS. K.ChorellE.Wittung-StafshedeP. (2015c). Insulin-degrading enzyme is activated by the C-terminus of alpha-synuclein. Biochem. Biophys. Res. Commun.466, 192–195. doi: 10.1016/j.bbrc.2015.09.002

  • CrossRef
  • Google Scholar

• 403

  ShavaliS.CarlsonE. C.SwinscoeJ. C.EbadiM. (2004). 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells. J. Neurosci. Res.76, 563–571. doi: 10.1002/jnr.20082

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 404

  ShererT. B.BetarbetR.TestaC. M.SeoB. B.RichardsonJ. R.KimJ. H.et al. (2003). Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci.23, 10756–10764. doi: 10.1523/JNEUROSCI.23-34-10756.2003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 405

  ShibasakiY.BaillieD. A.St ClairD.BrookesA. J. (1995). High-resolution mapping of SNCA encoding alpha-synuclein, the non-A beta component of Alzheimer's disease amyloid precursor, to human chromosome 4q21.3-->q22 by fluorescence in situ hybridization. Cytogenet. Cell Genet.71, 54–55.

  • Google Scholar

• 406

  ShuklaJ. J.StefanovaN.BushA. I.MccollG.FinkelsteinD. I.McallumE. J. (2021). Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. Neurobiol. Dis.159:105509. doi: 10.1016/j.nbd.2021.105509

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 407

  ShultsC. W. (2005). Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol. Ther.107, 120–130. doi: 10.1016/j.pharmthera.2005.02.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 408

  ShultsC. W.HaasR. H.PassovD.BealM. F. (1997). Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol.42, 261–264. doi: 10.1002/ana.410420221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 409

  ShultsC. W.SchapiraA. H. (2001). A cue to queue for CoQ?Neurology57, 375–376. doi: 10.1212/WNL.57.3.375

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 410

  SimonC.SogaT.OkanoH. J.ParharI. (2021). Alpha-synuclein-mediated neurodegeneration in dementia with Lewy bodies: the pathobiology of a paradox. Cell Biosci.11:196. doi: 10.1186/s13578-021-00709-y

  • CrossRef
  • Google Scholar

• 411

  SimuniT.FiskeB.MerchantK.CoffeyC. S.KlingnerE.Caspell-GarciaC.et al. (2021). Efficacy of Nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial. JAMA Neurol.78, 312–320. doi: 10.1001/jamaneurol.2020.4725

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 412

  SinghA.Boldin-AdamskyS.ThimmulappaR. K.RathS. K.AshushH.CoulterJ.et al. (2008). RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res.68, 7975–7984. doi: 10.1158/0008-5472.CAN-08-1401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 413

  SmithW. W.JiangH.PeiZ.TanakaY.MoritaH.SawaA.et al. (2005a). Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum. Mol. Genet.14, 3801–3811. doi: 10.1093/hmg/ddi396

  • CrossRef
  • Google Scholar

• 414

  SmithW. W.MargolisR. L.LiX.TroncosoJ. C.LeeM. K.DawsonV. L.et al. (2005b). Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci.25, 5544–5552. doi: 10.1523/JNEUROSCI.0482-05.2005

  • CrossRef
  • Google Scholar

• 415

  SohmiyaM.TanakaM.TakN. W.YanagisawaM.TaninoY.SuzukiY.et al. (2004). Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J. Neurol. Sci.223, 161–166. doi: 10.1016/j.jns.2004.05.007

  • CrossRef
  • Google Scholar

• 416

  SongM. K.AdamsL.LeeJ. H.KimY. S. (2022). NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-alpha-synuclein mouse model of Parkinson's disease. PLoS One17:e0272085. doi: 10.1371/journal.pone.0272085

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 417

  SonustunB.AltayM. F.StrandC.EbanksK.HondhamuniG.WarnerT. T.et al. (2022). Pathological relevance of Post-Translationally modified alpha-synuclein (pSer87, pSer129, nTyr39) in idiopathic Parkinson's Disease and multiple system atrophy. Cells11:906. doi: 10.3390/cells11050906

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 418

  SorrentinoL.CossuF.MilaniM.AlivertiA.MastrangeloE. (2017). Structural bases of the altered catalytic properties of a pathogenic variant of apoptosis inducing factor. Biochem. Biophys. Res. Commun.490, 1011–1017. doi: 10.1016/j.bbrc.2017.06.156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 419

  SouzaJ. M.GiassonB. I.ChenQ.LeeV. M.IschiropoulosH. (2000). Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem.275, 18344–18349. doi: 10.1074/jbc.M000206200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 420

  SpillantiniM. G. (1999). Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat. Disord.5, 157–162. doi: 10.1016/S1353-8020(99)00031-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 421

  SpillantiniM. G.CrowtherR. A.JakesR.HasegawaM.GoedertM. (1998). Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A.95, 6469–6473. doi: 10.1073/pnas.95.11.6469

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 422

  SpillantiniM. G.GoedertM. (2016). Synucleinopathies: past, present and future. Neuropathol. Appl. Neurobiol.42, 3–5. doi: 10.1111/nan.12311

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 423

  SpillantiniM. G.SchmidtM. L.LeeV. M.TrojanowskiJ. Q.JakesR.GoedertM. (1997). Alpha-synuclein in Lewy bodies. Nature388, 839–840. doi: 10.1038/42166

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 424

  SprengerF. S.StefanovaN.GelpiE.SeppiK.Navarro-OtanoJ.OffnerF.et al. (2015). Enteric nervous system alpha-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology85, 1761–1768. doi: 10.1212/WNL.0000000000002126

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 425

  St LaurentR.ObrienL. M.AhmadS. T. (2013). Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience246, 382–390. doi: 10.1016/j.neuroscience.2013.04.037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 426

  StefanisL. (2012). Alpha-synuclein in Parkinson's disease. Cold Spring Harb. Perspect. Med.2:a009399. doi: 10.1101/cshperspect.a009399

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 427

  StefanisL.EmmanouilidouE.PantazopoulouM.KirikD.VekrellisK.TofarisG. K. (2019). How is alpha-synuclein cleared from the cell?J. Neurochem.150, 577–590. doi: 10.1111/jnc.14704

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 428

  StefansonA. L.BakovicM. (2014). Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients6, 3777–3801. doi: 10.3390/nu6093777

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 429

  StewartT.SossiV.AaslyJ. O.WszolekZ. K.UittiR. J.HasegawaK.et al. (2015). Phosphorylated alpha-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol. Commun.3:7. doi: 10.1186/s40478-015-0185-3

  • CrossRef
  • Google Scholar

• 430

  StoesslA. J. (2016). Salivary gland biopsy for diagnosis of Parkinson's disease?Lancet Neurol.15, 654–656. doi: 10.1016/S1474-4422(16)30031-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 431

  StokholmM. G.DanielsenE. H.Hamilton-DutoitS. J.BorghammerP. (2016). Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol.79, 940–949. doi: 10.1002/ana.24648

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 432

  SudnikovichE. J.MaksimchikY. Z.ZabrodskayaS. V.KubyshinV. L.LapshinaE. A.BryszewskaM.et al. (2007). Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur. J. Pharmacol.569, 180–187. doi: 10.1016/j.ejphar.2007.05.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 433

  SugenoN.TakedaA.HasegawaT.KobayashiM.KikuchiA.MoriF.et al. (2008). Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J. Biol. Chem.283, 23179–23188. doi: 10.1074/jbc.M802223200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 434

  SunX.MajumderP.ShioyaH.WuF.KumarS.WeichselbaumR.et al. (2000). Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J. Biol. Chem.275, 17237–17240. doi: 10.1074/jbc.C000099200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 435

  SuoH.WangP.TongJ.CaiL.LiuJ.HuangD.et al. (2015). NRSF is an essential mediator for the neuroprotection of trichostatin a in the MPTP mouse model of Parkinson's disease. Neuropharmacology99, 67–78. doi: 10.1016/j.neuropharm.2015.07.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 436

  SvenningssonP.WirdefeldtK.YinL.FangF.MarkakiI.EfendicS.et al. (2016). Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study. Mov. Disord.31, 1422–1423. doi: 10.1002/mds.26734

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 437

  TakahashiM.KanukaH.FujiwaraH.KoyamaA.HasegawaM.MiuraM.et al. (2003). Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett.336, 155–158. doi: 10.1016/S0304-3940(02)01258-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 438

  TakahashiT.YamashitaH.NakamuraT.NaganoY.NakamuraS. (2002). Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res.938, 73–80. doi: 10.1016/S0006-8993(02)02498-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 439

  TakamatsuY.FujitaM.HoG. J.WadaR.SugamaS.TakenouchiT.et al. (2018). Motor and nonmotor symptoms of Parkinson's disease: antagonistic pleiotropy phenomena derived from alpha-synuclein evolvability?Parkinsons Dis.2018:5789424. doi: 10.1155/2018/5789424

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 440

  TaneiZ. I.SaitoY.ItoS.MatsubaraT.MotodaA.YamazakiM.et al. (2021). Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. Acta Neuropathol.141, 25–37. doi: 10.1007/s00401-020-02233-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 441

  TathamM. H.JaffrayE.VaughanO. A.DesterroJ. M.BottingC. H.NaismithJ. H.et al. (2001). Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem.276, 35368–35374. doi: 10.1074/jbc.M104214200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 442

  TavassolyO.YueJ.VocadloD. J. (2021). Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of alpha-synuclein preformed fibrils. FEBS J.288, 452–470. doi: 10.1111/febs.15349

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 443

  TeleanuD. M.NiculescuA. G.LunguI.RaduC. I.VladacencoO.RozaE.et al. (2022). An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int. J. Mol. Sci.23:5938. doi: 10.3390/ijms23115938

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 444

  TenreiroS.Reimao-PintoM. M.AntasP.RinoJ.WawrzyckaD.MacedoD.et al. (2014). Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet.10:e1004302. doi: 10.1371/journal.pgen.1004302

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 445

  TetzlaffJ. E.PutchaP.OuteiroT. F.IvanovA.BerezovskaO.HymanB. T.et al. (2008). CHIP targets toxic alpha-Synuclein oligomers for degradation. J. Biol. Chem.283, 17962–17968. doi: 10.1074/jbc.M802283200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 446

  ThorneN. J.TumbarelloD. A. (2022). The relationship of alpha-synuclein to mitochondrial dynamics and quality control. Front. Mol. Neurosci.15:947191. doi: 10.3389/fnmol.2022.947191

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 447

  TianC.LiuG.GaoL.SoltysD.PanC.StewartT.et al. (2019). Erythrocytic alpha-Synuclein as a potential biomarker for Parkinson's disease. Transl. Neurodegener.8:15. doi: 10.1186/s40035-019-0155-y

  • CrossRef
  • Google Scholar

• 448

  TofarisG. K.KimH. T.HourezR.JungJ. W.KimK. P.GoldbergA. L. (2011). Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. U. S. A.108, 17004–17009. doi: 10.1073/pnas.1109356108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 449

  TofarisG. K.LayfieldR.SpillantiniM. G. (2001). Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett.509, 22–26. doi: 10.1016/S0014-5793(01)03115-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 450

  TofarisG. K.RazzaqA.GhettiB.LilleyK. S.SpillantiniM. G. (2003). Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem.278, 44405–44411. doi: 10.1074/jbc.M308041200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 451

  TokerL.TranG. T.SundaresanJ.TysnesO. B.AlvesG.HaugarvollK.et al. (2021). Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. Mol. Neurodegener.16:31. doi: 10.1186/s13024-021-00450-7

  • CrossRef
  • Google Scholar

• 452

  TokudaT.QureshiM. M.ArdahM. T.VargheseS.ShehabS. A.KasaiT.et al. (2010). Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology75, 1766–1772. doi: 10.1212/WNL.0b013e3181fd613b

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 453

  TremblayM. A.AckerC. M.DaviesP. (2010). Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J. Alzheimers Dis.19, 721–733. doi: 10.3233/JAD-2010-1271

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 454

  TrezziJ. P.GalozziS.JaegerC.BarkovitsK.BrockmannK.MaetzlerW.et al. (2017). Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. Mov. Disord.32, 1401–1408. doi: 10.1002/mds.27132

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 455

  UddinM. S.MamunA. A.JakariaM.ThangapandiyanS.AhmadJ.RahmanM. A.et al. (2020). Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci. Total Environ.707:135624. doi: 10.1016/j.scitotenv.2019.135624

  • CrossRef
  • Google Scholar

• 456

  UedaK.FukushimaH.MasliahE.XiaY.IwaiA.YoshimotoM.et al. (1993). Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A.90, 11282–11286. doi: 10.1073/pnas.90.23.11282

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 457

  UllmanO.FisherC. K.StultzC. M. (2011). Explaining the structural plasticity of alpha-synuclein. J. Am. Chem. Soc.133, 19536–19546. doi: 10.1021/ja208657z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 458

  VaccariC.GrottoD.PereiraT. D. V.De CamargoJ. L. V.LopesL. C. (2021). GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: translational systematic review and meta-analysis protocol of clinical and preclinical studies. PLoS One16:e0255726. doi: 10.1371/journal.pone.0255726

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 459

  VamvacaK.VollesM. J.LansburyP. T.Jr. (2009). The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J. Mol. Biol.389, 413–424. doi: 10.1016/j.jmb.2009.03.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 460

  VancraenenbroeckR.LobbestaelE.MaeyerM. D.BaekelandtV.TaymansJ. M. (2011). Kinases as targets for Parkinson's disease: from genetics to therapy. CNS Neurol. Disord. Drug Targets10, 724–740. doi: 10.2174/187152711797247858

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 461

  Vicente MirandaH.CassioR.Correia-GuedesL.GomesM. A.ChegaoA.MirandaE.et al. (2017a). Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Sci. Rep.7:13713. doi: 10.1038/s41598-017-14175-5

  • CrossRef
  • Google Scholar

• 462

  Vicente MirandaH.OuteiroT. F. (2010). The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol.221, 13–25. doi: 10.1002/path.2682

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 463

  Vicente MirandaH.SzegoE. M.OliveiraL. M. A.BredaC.DarendeliogluE.De OliveiraR. M.et al. (2017b). Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain140, 1399–1419. doi: 10.1093/brain/awx056

  • CrossRef
  • Google Scholar

• 464

  VijayakumaranS.NakamuraY.HenleyJ. M.PountneyD. L. (2019). Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates. Mol. Cell. Neurosci.101:103416. doi: 10.1016/j.mcn.2019.103416

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 465

  VilasD.IranzoA.TolosaE.AldecoaI.BerenguerJ.VilasecaI.et al. (2016). Assessment of alpha-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol.15, 708–718. doi: 10.1016/S1474-4422(16)00080-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 466

  VivacquaG.MasonM.De BartoloM. I.WegrzynowiczM.CaloL.BelvisiD.et al. (2023). Salivary alpha-synuclein RT-QuIC correlates with disease severity in de novo Parkinson's disease. Mov. Disord.38, 153–155. doi: 10.1002/mds.29246

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 467

  VivacquaG.SuppaA.MancinelliR.BelvisiD.FabbriniA.CostanzoM.et al. (2019). Salivary alpha-synuclein in the diagnosis of Parkinson's disease and progressive supranuclear palsy. Parkinsonism Relat. Disord.63, 143–148. doi: 10.1016/j.parkreldis.2019.02.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 468

  WahlqvistM. L.LeeM. S.HsuC. C.ChuangS. Y.LeeJ. T.TsaiH. N. (2012). Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord.18, 753–758. doi: 10.1016/j.parkreldis.2012.03.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 469

  WakabayashiK. (2020). Where and how alpha-synuclein pathology spreads in Parkinson's disease. Neuropathology40, 415–425. doi: 10.1111/neup.12691

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 470

  WakabayashiK.MikiY.TanjiK.MoriF. (2022). Neuropathology of multiple system atrophy, a glioneuronal degenerative disease. Cerebellum, doi: 10.1007/s12311-022-01407-2 [Epub ahead of print].

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 471

  WangD. B.KinoshitaC.KinoshitaY.SopherB. L.UoT.LeeR. J.et al. (2019). Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1. Brain Pathol.29, 164–175. doi: 10.1111/bpa.12647

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 472

  WangN.GarciaJ.FreemanR.GibbonsC. H. (2020a). Phosphorylated alpha-synuclein within cutaneous autonomic nerves of patients with Parkinson's disease: the implications of sample thickness on results. J. Histochem. Cytochem.68, 669–678. doi: 10.1369/0022155420960250

  • CrossRef
  • Google Scholar

• 473

  WangW.PerovicI.ChittuluruJ.KaganovichA.NguyenL. T.LiaoJ.et al. (2011). A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U. S. A.108, 17797–17802. doi: 10.1073/pnas.1113260108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 474

  WangX. Y.KangW. Y.YangQ.ZhangL. Y.ChenS. D.LiuJ. (2014). Using gastrocnemius sEMG and plasma alpha-synuclein for the prediction of freezing of gait in Parkinson's disease patients. PLoS One9:e89353. doi: 10.1371/journal.pone.0116382

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 475

  WangZ.BeckerK.DonadioV.SiedlakS.YuanJ.RezaeeM.et al. (2020b). Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol.78, 1–11. doi: 10.1001/jamaneurol.2020.3311

  • CrossRef
  • Google Scholar

• 476

  WatsonJ. B.HatamiA.DavidH.MasliahE.RobertsK.EvansC. E.et al. (2009). Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience159, 501–513. doi: 10.1016/j.neuroscience.2009.01.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 477

  WaxmanE. A.GiassonB. I. (2011). Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein. J. Neurosci. Res.89, 231–247. doi: 10.1002/jnr.22537

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 478

  WebbJ. L.RavikumarB.AtkinsJ.SkepperJ. N.RubinszteinD. C. (2003). Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem.278, 25009–25013. doi: 10.1074/jbc.M300227200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 479

  WeetmanJ.WongM. B.SharryS.Rcom-H'cheo-GauthierA.GaiW. P.MeedeniyaA.et al. (2013). Increased SUMO-1 expression in the unilateral rotenone-lesioned mouse model of Parkinson's disease. Neurosci. Lett.544, 119–124. doi: 10.1016/j.neulet.2013.03.057

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 480

  WeissmanA. M. (2001). Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol.2, 169–178. doi: 10.1038/35056563

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 481

  WenzT. (2013). Regulation of mitochondrial biogenesis and PGC-1alpha under cellular stress. Mitochondrion13, 134–142. doi: 10.1016/j.mito.2013.01.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 482

  WernerM. H.OlanowC. W. (2022). Parkinson's disease modification through Abl kinase inhibition: an opportunity. Mov. Disord.37, 6–15. doi: 10.1002/mds.28858

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 483

  WilkaniecA.StrosznajderJ. B.AdamczykA. (2013). Toxicity of extracellular secreted alpha-synuclein: its role in nitrosative stress and neurodegeneration. Neurochem. Int.62, 776–783. doi: 10.1016/j.neuint.2013.02.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 484

  WilkinsonK. A.HenleyJ. M. (2010). Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J.428, 133–145. doi: 10.1042/BJ20100158

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 485

  WilsonC. J.CallawayJ. C. (2000). Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol.83, 3084–3100. doi: 10.1152/jn.2000.83.5.3084

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 486

  WiniarskaK.FraczykT.MalinskaD.DrozakJ.BrylaJ. (2006). Melatonin attenuates diabetes-induced oxidative stress in rabbits. J. Pineal Res.40, 168–176. doi: 10.1111/j.1600-079X.2005.00295.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 487

  WinklhoferK. F.HaassC. (2010). Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta1802, 29–44. doi: 10.1016/j.bbadis.2009.08.013

  • CrossRef
  • Google Scholar

• 488

  WittM.BormannK.GudziolV.PehlkeK.BarthK.MinoviA.et al. (2009). Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov. Disord.24, 906–914. doi: 10.1002/mds.22464

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 489

  WuT.ThazhathS. S.MaratheC. S.BoundM. J.JonesK. L.HorowitzM.et al. (2015). Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males. Nutr. Diabetes5:e156. doi: 10.1038/nutd.2015.6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 490

  WuY.GuoS. W. (2008). Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur. J. Obstet. Gynecol. Reprod. Biol.137, 198–203. doi: 10.1016/j.ejogrb.2007.02.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 491

  XieX.YuC.ZhouJ.XiaoQ.ShenQ.XiongZ.et al. (2020). Nicotinamide mononucleotide ameliorates the depression-like behaviors and is associated with attenuating the disruption of mitochondrial bioenergetics in depressed mice. J. Affect. Disord.263, 166–174. doi: 10.1016/j.jad.2019.11.147

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 492

  YangY. W.HsiehT. F.LiC. I.LiuC. S.LinW. Y.ChiangJ. H.et al. (2017). Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore)96:e5921. doi: 10.1097/MD.0000000000009419

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 493

  YuY.ZhangL.LiX.RunX.LiangZ.LiY.et al. (2012). Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One7:e35277. doi: 10.1371/journal.pone.0051967

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 494

  YuZ.XuX.XiangZ.ZhouJ.ZhangZ.HuC.et al. (2010). Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One5:e9956. doi: 10.1371/journal.pone.0015623

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 495

  YunS. P..KimD.KimS.KimS.KaruppagounderS. S.KwonS. H.et al. (2018). Biopsiesalpha-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener.13:1. doi: 10.1186/s13024-017-0233-5

  • CrossRef
  • Google Scholar

• 496

  YuzwaS. A.CheungA. H.OkonM.McintoshL. P.VocadloD. J. (2014a). O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J. Mol. Biol.426, 1736–1752. doi: 10.1016/j.jmb.2014.01.004

  • CrossRef
  • Google Scholar

• 497

  YuzwaS. A.MacauleyM. S.HeinonenJ. E.ShanX.DennisR. J.HeY.et al. (2008). A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol.4, 483–490. doi: 10.1038/nchembio.96

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 498

  YuzwaS. A.ShanX.JonesB. A.ZhaoG.WoodwardM. L.LiX.et al. (2014b). Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. Mol. Neurodegener.9:42. doi: 10.1186/1750-1326-9-42

  • CrossRef
  • Google Scholar

• 499

  YuzwaS. A.ShanX.MacauleyM. S.ClarkT.SkorobogatkoY.VossellerK.et al. (2012). Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol.8, 393–399. doi: 10.1038/nchembio.797

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 500

  ZangeL.NoackC.HahnK.StenzelW.LippA. (2015). Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain138, 2310–2321. doi: 10.1093/brain/awv138

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 501

  ZhangF.HuY.HuangP.TolemanC. A.PatersonA. J.KudlowJ. E. (2007). Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem.282, 22460–22471. doi: 10.1074/jbc.M702439200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 502

  ZhangJ.LeiH.ChenY.MaY. T.JiangF.TanJ.et al. (2017). Enzymatic O-GlcNAcylation of alpha-synuclein reduces aggregation and increases SDS-resistant soluble oligomers. Neurosci. Lett.655, 90–94. doi: 10.1016/j.neulet.2017.06.034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 503

  ZhangJ.LiX.LiJ. D. (2019). The roles of post-translational modifications on alpha-synuclein in the pathogenesis of Parkinson's diseases. Front. Neurosci.13:381. doi: 10.3389/fnins.2019.00381

  • CrossRef
  • Google Scholar

• 504

  ZhangJ.PerryG.SmithM. A.RobertsonD.OlsonS. J.GrahamD. G.et al. (1999). Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol.154, 1423–1429. doi: 10.1016/S0002-9440(10)65396-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 505

  ZhangL. F.YuX. L.JiM.LiuS. Y.WuX. L.WangY. J.et al. (2018). Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T alpha-synuclein mouse model of Parkinson's disease. Food Funct.9, 6414–6426. doi: 10.1039/C8FO00964C

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 506

  ZhangL. Y.JinQ. Q.HolscherC.LiL. (2021). Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen. Res.16, 1660–1670. doi: 10.4103/1673-5374.303045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 507

  ZhangS.XieJ.XiaY.YuS.GuZ.FengR.et al. (2015). LK6/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration. Sci. Rep.5:12564. doi: 10.1038/srep12564

  • CrossRef
  • Google Scholar

• 508

  ZhangY. C.GanF. F.ShelarS. B.NgK. Y.ChewE. H. (2013). Antioxidant and Nrf2 inducing activities of luteolin, a flavonoid constituent in Ixeris sonchifolia Hance, provide neuroprotective effects against ischemia-induced cellular injury. Food Chem. Toxicol.59, 272–280. doi: 10.1016/j.fct.2013.05.058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 509

  ZhaoX.ZhangM.LiC.JiangX.SuY.ZhangY. (2019). Benefits of vitamins in the treatment of Parkinson's Disease. Oxidative Med. Cell. Longev.2019:9426867. doi: 10.1155/2019/9426867

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 510

  ZhongC. B.ChenQ. Q.HaikalC.LiW.SvanbergssonA.DiepenbroekM.et al. (2017). Age-dependent alpha-synuclein accumulation and phosphorylation in the enteric nervous system in a transgenic mouse model of Parkinson's disease. Neurosci. Bull.33, 483–492. doi: 10.1007/s12264-017-0179-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 511

  ZhouC.JiJ.ShiM.YangL.YuY.LiuB.et al. (2014). Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells. Mol. Med. Rep.10, 2729–2735. doi: 10.3892/mmr.2014.2548

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 512

  ZhouW.BercuryK.CummiskeyJ.LuongN.LebinJ.FreedC. R. (2011). Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem.286, 14941–14951. doi: 10.1074/jbc.M110.211029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 513

  ZhouW.RyanJ. J.ZhouH. (2004). Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem.279, 32262–32268. doi: 10.1074/jbc.M404173200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 514

  ZimprichA.Benet-PagesA.StruhalW.GrafE.EckS. H.OffmanM. N.et al. (2011). A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet.89, 168–175. doi: 10.1016/j.ajhg.2011.06.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar